drug1_db stringlengths 7 7 | drug2_db stringlengths 7 7 | drug1_id int64 0 1.69k | drug2_id int64 0 1.69k | drug_pair listlengths 2 2 | drug1_name stringlengths 4 85 | drug2_name stringlengths 4 85 | drug1_desc stringlengths 27 1.09k | drug2_desc stringlengths 27 6.14k | label stringclasses 3
values | label_idx int64 0 2 | all_paths listlengths 1 10 | all_paths_str listlengths 1 10 | path_str stringlengths 0 3.57k |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
DB01110 | DB01166 | 86 | 477 | [
"DDInter1209",
"DDInter379"
] | Miconazole | Cilostazol | Miconazole is a broad-spectrum azole antifungal with some activity against Gram-positive bacteria as well. It is widely used to treat mucosal yeast infections, including both oral and vaginal infections; although intravenous miconazole is no longer available, a wide variety of suppositories, creams, gels, and tablet-ba... | Cilostazol is a quinolinone derivative and antiplatelet agent with vasodilating properties that has been used in the symptomatic treatment of intermittent claudication in patients with peripheral ischaemia. It is marketed under the brand name Pletal by Otsuka Pharmaceutical Co.. Cilostazol works by inhibiting both prim... | Moderate | 1 | [
[
[
86,
24,
477
]
],
[
[
86,
6,
8374
],
[
8374,
45,
477
]
],
[
[
86,
21,
29340
],
[
29340,
60,
477
]
],
[
[
86,
64,
126
],
[
126,
23... | [
[
[
"Miconazole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cilostazol"
]
],
[
[
"Miconazole",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)",... | Miconazole (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Cilostazol (Compound)
Miconazole (Compound) causes Stevens-Johnson syndrome (Side Effect) and Stevens-Johnson syndrome (Side Effect) is caused by Cilostazol (Compound)
Miconazole may lead to a major life threatening interaction when taken with Warf... |
DB00215 | DB00427 | 1,230 | 1,233 | [
"DDInter388",
"DDInter1879"
] | Citalopram | Triprolidine | Citalopram is an antidepressant belonging to the class of selective _serotonin-reuptake inhibitors_ (SSRIs) widely used to treat the symptoms of depression. It is a racemic bicyclic phthalate derivate and is the only compound with a tertiary amine and 2 nitrogen-containing metabolites among all SSRIs.[A261316,A14720] C... | First generation histamine H1 antagonist used in allergic rhinitis; asthma; and urticaria. It is a component of cough and cold medicines. It may cause drowsiness. | Moderate | 1 | [
[
[
1230,
24,
1233
]
],
[
[
1230,
6,
12523
],
[
12523,
45,
1233
]
],
[
[
1230,
24,
104
],
[
104,
63,
1233
]
],
[
[
1230,
25,
506
],
[
506,... | [
[
[
"Citalopram",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Triprolidine"
]
],
[
[
"Citalopram",
"{u} (Compound) binds {v} (Gene)",
"CYP2D6"
],
[
"CYP2D6",
"{u} (Gene) is bound by {v} (Compound)... | Citalopram (Compound) binds CYP2D6 (Gene) and CYP2D6 (Gene) is bound by Triprolidine (Compound)
Citalopram may cause a moderate interaction that could exacerbate diseases when taken with Methdilazine and Methdilazine may cause a moderate interaction that could exacerbate diseases when taken with Triprolidine
Citalopram... |
DB00328 | DB00860 | 831 | 891 | [
"DDInter921",
"DDInter1513"
] | Indomethacin | Prednisolone | Indometacin, or indomethacin, is a non-steroidal anti-inflammatory drug (NSAID) with anti-inflammatory, analgesic, and antipyretic properties. NSAIDs consist of agents that are structurally unrelated; the NSAID chemical classification of indometacin is an indole-acetic acid derivative with the chemical name 1- (p-chlor... | Prednisolone is a glucocorticoid similar to [cortisol] used for its anti-inflammatory, immunosuppressive, anti-neoplastic, and vasoconstrictive effects. Prednisolone was granted FDA approval on 21 June 1955. | Moderate | 1 | [
[
[
831,
24,
891
]
],
[
[
831,
24,
175
],
[
175,
40,
891
]
],
[
[
831,
24,
167
],
[
167,
1,
891
]
],
[
[
831,
10,
11591
],
[
11591,
... | [
[
[
"Indomethacin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Prednisolone"
]
],
[
[
"Indomethacin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Triamcinolone"
],... | Indomethacin may cause a moderate interaction that could exacerbate diseases when taken with Triamcinolone and Triamcinolone (Compound) resembles Prednisolone (Compound)
Indomethacin may cause a moderate interaction that could exacerbate diseases when taken with Hydrocortisone and Hydrocortisone (Compound) resembles Pr... |
DB00968 | DB01142 | 1,551 | 1,264 | [
"DDInter1185",
"DDInter593"
] | Methyldopa | Doxepin | Methyldopa, or α-methyldopa, is a centrally acting sympatholytic agent and an antihypertensive agent. It is an analog of DOPA (3,4‐hydroxyphenylanine), and it is a prodrug, meaning that the drug requires biotransformation to an active metabolite for therapeutic effects. Methyldopa works by binding to alpha(α)-2 adrener... | Doxepin is a psychotropic agent with antidepressant and anxiolytic properties. It is a tertiary amine that can be presented as (E) and (Z) stereoisomers with the (Z) stereoisomer corresponding to [cidoxepin]. Doxepin commonly produces a 5:1 (E):(Z) racemic mixture. In a strict sense, doxepin is not a tricyclic antidepr... | Minor | 0 | [
[
[
1551,
23,
1264
]
],
[
[
1551,
24,
401
],
[
401,
24,
1264
]
],
[
[
1551,
24,
649
],
[
649,
63,
1264
]
],
[
[
1551,
6,
5372
],
[
5372,
... | [
[
[
"Methyldopa",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Doxepin"
]
],
[
[
"Methyldopa",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Promethazine"
],
[
... | Methyldopa may cause a moderate interaction that could exacerbate diseases when taken with Promethazine and Promethazine may cause a moderate interaction that could exacerbate diseases when taken with Doxepin
Methyldopa may cause a moderate interaction that could exacerbate diseases when taken with Clofedanol and Clofe... |
DB00254 | DB00364 | 964 | 417 | [
"DDInter598",
"DDInter1717"
] | Doxycycline | Sucralfate | Doxycycline is a broad-spectrum antibiotic synthetically derived from [oxytetracycline]. It is a second-generation tetracycline that was first discovered in 1967. Second-generation tetracyclines exhibit lesser toxicity than first-generation tetracyclines. Doxycycline is used to treat a wide variety of gram-positive and... | Sucralfate is a medication that is widely used to prevent and treat a number of diseases in the gastrointestinal tract such as duodenal ulcers [FDA label], gastro-esophageal reflux disease (GERD), gastritis, peptic ulcer disease, stress ulcer, in addition to dyspepsia . It is considered a _cytoprotective agent_, protec... | Moderate | 1 | [
[
[
964,
24,
417
]
],
[
[
964,
24,
1031
],
[
1031,
23,
417
]
],
[
[
964,
24,
1482
],
[
1482,
63,
417
]
],
[
[
964,
1,
1545
],
[
1545,
... | [
[
[
"Doxycycline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sucralfate"
]
],
[
[
"Doxycycline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Theophylline"
],
... | Doxycycline may cause a moderate interaction that could exacerbate diseases when taken with Theophylline and Theophylline may cause a minor interaction that can limit clinical effects when taken with Sucralfate
Doxycycline may cause a moderate interaction that could exacerbate diseases when taken with Digitoxin and Dig... |
DB01579 | DB09472 | 341 | 1,383 | [
"DDInter1439",
"DDInter1693"
] | Phendimetrazine | Sodium sulfate | Phendimetrazine is a weight loss medication. Phendimetrazine is chemically related to amphetamines and is a Schedule III drug under the Convention on Psychotropic Substances and in the US since 1970. | Sodium Sulfate Anhydrous is the anhydrous, sodium salt form of sulfuric acid. Sodium sulfate anhydrous disassociates in water to provide sodium ions and sulfate ions. Sodium ion is the principal cation of the extracellular fluid and plays a large part in the therapy of fluid and electrolyte disturbances. Sodium sulfate... | Moderate | 1 | [
[
[
341,
24,
1383
]
],
[
[
341,
64,
1466
],
[
1466,
24,
1383
]
],
[
[
341,
63,
104
],
[
104,
24,
1383
]
],
[
[
341,
64,
1466
],
[
1466,
... | [
[
[
"Phendimetrazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sodium sulfate"
]
],
[
[
"Phendimetrazine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Phenylpropanolamine"
],
... | Phendimetrazine may lead to a major life threatening interaction when taken with Phenylpropanolamine and Phenylpropanolamine may cause a moderate interaction that could exacerbate diseases when taken with Sodium sulfate
Phendimetrazine may cause a moderate interaction that could exacerbate diseases when taken with Meth... |
DB01129 | DB12010 | 379 | 214 | [
"DDInter1559",
"DDInter785"
] | Rabeprazole | Fostamatinib | Rabeprazole is an antiulcer drug in the class of proton pump inhibitors. It is a prodrug - in the acid environment of the parietal cells it turns into active sulphenamide form. Rabeprazole inhibits the H+, K+ATPase of the coating gastric cells and dose-dependent oppresses basal and stimulated gastric acid secretion. | Fostamatinib has been investigated for the treatment and basic science of Rheumatoid Arthritis and Immune Thrombocytopenic Purpura (ITP). It was approved on April 17, 2018, under the trade name Tavalisse for use in ITP [L2644, FDA Label]. Fostamatinib has also been granted orphan drug status by the FDA . Recently, fost... | Moderate | 1 | [
[
[
379,
24,
214
]
],
[
[
379,
63,
723
],
[
723,
24,
214
]
],
[
[
379,
25,
1250
],
[
1250,
24,
214
]
],
[
[
379,
24,
875
],
[
875,
2... | [
[
[
"Rabeprazole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fostamatinib"
]
],
[
[
"Rabeprazole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Aprepitant"
],
... | Rabeprazole may cause a moderate interaction that could exacerbate diseases when taken with Aprepitant and Aprepitant may cause a moderate interaction that could exacerbate diseases when taken with Fostamatinib
Rabeprazole may lead to a major life threatening interaction when taken with Pazopanib and Pazopanib may caus... |
DB00059 | DB00459 | 1,560 | 640 | [
"DDInter1404",
"DDInter21"
] | Pegaspargase | Acitretin | Pegaspargase is a conjugate of monomethoxypolyethylene glycol (mPEG) and L-asparaginase (L-asparagine amidohydrolase), an asparagine-specific enzyme that converts L-asparagine into aspartic acid and ammonia. Asparagine is an amino acid that is vital for cell survival. In humans, most normal tissues can produce asparagi... | An oral retinoid effective in the treatment of psoriasis. It is the major metabolite of etretinate with the advantage of a much shorter half-life when compared with etretinate. | Moderate | 1 | [
[
[
1560,
24,
640
]
],
[
[
1560,
24,
1517
],
[
1517,
64,
640
]
],
[
[
1560,
24,
267
],
[
267,
63,
640
]
],
[
[
1560,
24,
912
],
[
912,
... | [
[
[
"Pegaspargase",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Acitretin"
]
],
[
[
"Pegaspargase",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Isotretinoin"
],
... | Pegaspargase may cause a moderate interaction that could exacerbate diseases when taken with Isotretinoin and Isotretinoin may lead to a major life threatening interaction when taken with Acitretin
Pegaspargase may cause a moderate interaction that could exacerbate diseases when taken with Naltrexone and Naltrexone may... |
DB09098 | DB13928 | 98 | 1,385 | [
"DDInter1700",
"DDInter1660"
] | Somatrem | Semaglutide | Despite the ability of almost all contemporary recombinant growth hormones to cause definite and demonstrable increases in growth rate in patients who are administered the drug, the use of these agents continues to be mired in persistent bioethical debate. Such discussion revolves around whether patients' natural dispo... | Semaglutide is a glucagon-like peptide 1 (GLP-1) analog used to manage type 2 diabetes along with lifestyle changes, such as dietary restrictions and increased physical activity.[A31421,L8681] Other members of this drug class include [Exenatide] and [Liraglutide]. Semaglutide was developed by Novo Nordisk and approved ... | Moderate | 1 | [
[
[
98,
24,
1385
]
],
[
[
98,
63,
891
],
[
891,
24,
1385
]
],
[
[
98,
24,
1476
],
[
1476,
24,
1385
]
],
[
[
98,
62,
168
],
[
168,
24... | [
[
[
"Somatrem",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Semaglutide"
]
],
[
[
"Somatrem",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Prednisolone"
],
[
... | Somatrem may cause a moderate interaction that could exacerbate diseases when taken with Prednisolone and Prednisolone may cause a moderate interaction that could exacerbate diseases when taken with Semaglutide
Somatrem may cause a moderate interaction that could exacerbate diseases when taken with Brigatinib and Briga... |
DB01087 | DB08903 | 1,520 | 996 | [
"DDInter1520",
"DDInter170"
] | Primaquine | Bedaquiline | An aminoquinoline that is given by mouth to produce a radical cure and prevent relapse of vivax and ovale malarias following treatment with a blood schizontocide. It has also been used to prevent transmission of falciparum malaria by those returning to areas where there is a potential for re-introduction of malaria. Ad... | Bedaquiline is a bactericidal antimycobacterial drug belonging to the class of diarylquinoline. The quinolinic central heterocyclic nucleus with alcohol and amine side chains is responsible for bedaquiline-mediated antimycobacterial activity. Although it is closely related to fluoroquinolones, bedaquiline does not affe... | Major | 2 | [
[
[
1520,
25,
996
]
],
[
[
1520,
6,
8374
],
[
8374,
45,
996
]
],
[
[
1520,
21,
28722
],
[
28722,
60,
996
]
],
[
[
1520,
62,
112
],
[
112,
... | [
[
[
"Primaquine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Bedaquiline"
]
],
[
[
"Primaquine",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)",
"Bedaqu... | Primaquine (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Bedaquiline (Compound)
Primaquine (Compound) causes Nausea (Side Effect) and Nausea (Side Effect) is caused by Bedaquiline (Compound)
Primaquine may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metroni... |
DB00907 | DB06707 | 290 | 584 | [
"DDInter427",
"DDInter1060"
] | Cocaine (topical) | Levonordefrin | Cocaine can cause developmental toxicity and female reproductive toxicity according to an independent committee of scientific and health experts. | Levonordefrin acts as a topical nasal decongestant and vasoconstrictor, most often used in dentistry. | Major | 2 | [
[
[
290,
25,
584
]
],
[
[
290,
25,
817
],
[
817,
40,
584
]
],
[
[
290,
25,
1354
],
[
1354,
1,
584
]
],
[
[
290,
25,
1148
],
[
1148,
... | [
[
[
"Cocaine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Levonordefrin"
]
],
[
[
"Cocaine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Dopamine"
],
[
"Dopamine",
"{u} (Compoun... | Cocaine may lead to a major life threatening interaction when taken with Levonordefrin
Cocaine may lead to a major life threatening interaction when taken with Dopamine and Dopamine (Compound) resembles Levonordefrin (Compound)
Cocaine may lead to a major life threatening interaction when taken with Droxidopa and Droxi... |
DB00544 | DB15091 | 970 | 676 | [
"DDInter757",
"DDInter1901"
] | Fluorouracil | Upadacitinib | A pyrimidine analog that is an antineoplastic antimetabolite. It interferes with DNA synthesis by blocking the thymidylate synthetase conversion of deoxyuridylic acid to thymidylic acid. | Upadacitinib is an oral Janus kinase (JAK)1-selective inhibitor and a disease-modifying antirheumatic drug (DMARD) used in the treatment of rheumatoid arthritis to slow down disease progression. Rheumatoid arthritis is a chronic autoimmune inflammatory disease affecting the peripheral joints. It is characterized by syn... | Major | 2 | [
[
[
970,
25,
676
]
],
[
[
970,
63,
1461
],
[
1461,
23,
676
]
],
[
[
970,
24,
1430
],
[
1430,
24,
676
]
],
[
[
970,
63,
597
],
[
597,
... | [
[
[
"Fluorouracil",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Upadacitinib"
]
],
[
[
"Fluorouracil",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Vitamin E"
],
[
"Vitam... | Fluorouracil may cause a moderate interaction that could exacerbate diseases when taken with Vitamin E and Vitamin E may cause a minor interaction that can limit clinical effects when taken with Upadacitinib
Fluorouracil may cause a moderate interaction that could exacerbate diseases when taken with Sipuleucel-T and Si... |
DB01081 | DB01367 | 1,688 | 1,163 | [
"DDInter571",
"DDInter1572"
] | Diphenoxylate | Rasagiline | A meperidine congener used as an antidiarrheal, usually in combination with atropine. At high doses, it acts like morphine. Its unesterified metabolite difenoxin has similar properties and is used similarly. It has little or no analgesic activity. This medication is classified as a Schedule V under the Controlled Subst... | Rasagiline is an irreversible inhibitor of monoamine oxidase and is used as a monotherapy in early Parkinson's disease or as an adjunct therapy in more advanced cases. | Moderate | 1 | [
[
[
1688,
24,
1163
]
],
[
[
1688,
63,
662
],
[
662,
24,
1163
]
],
[
[
1688,
40,
1118
],
[
1118,
63,
1163
]
],
[
[
1688,
24,
649
],
[
649,
... | [
[
[
"Diphenoxylate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Rasagiline"
]
],
[
[
"Diphenoxylate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Carbinoxamine"
],... | Diphenoxylate may cause a moderate interaction that could exacerbate diseases when taken with Carbinoxamine and Carbinoxamine may cause a moderate interaction that could exacerbate diseases when taken with Rasagiline
Diphenoxylate (Compound) resembles Difenoxin (Compound) and Difenoxin may cause a moderate interaction ... |
DB00738 | DB06288 | 485 | 607 | [
"DDInter1420",
"DDInter77"
] | Pentamidine | Amisulpride | Antiprotozoal agent effective in trypanosomiasis, leishmaniasis, and some fungal infections; used in treatment of pneumocystis pneumonia in HIV-infected patients. It may cause diabetes mellitus, central nervous system damage, and other toxic effects. | Amisulpride is a benzamide derivative and a dopamine receptor antagonist that selectively works on dopamine D2 and D3 receptors. As an antipsychotic agent, amisulpride alleviates both positive and negative symptoms of schizophrenia, and it exhibits antidepressant properties in patients with psychiatric disorders, dysth... | Major | 2 | [
[
[
485,
25,
607
]
],
[
[
485,
21,
29232
],
[
29232,
60,
607
]
],
[
[
485,
23,
112
],
[
112,
23,
607
]
],
[
[
485,
24,
1559
],
[
1559,
... | [
[
[
"Pentamidine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Amisulpride"
]
],
[
[
"Pentamidine",
"{u} (Compound) causes {v} (Side Effect)",
"Urticaria"
],
[
"Urticaria",
"{u} (Side Effect) is caused by {v} (C... | Pentamidine (Compound) causes Urticaria (Side Effect) and Urticaria (Side Effect) is caused by Amisulpride (Compound)
Pentamidine may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Am... |
DB00662 | DB00690 | 717 | 1,216 | [
"DDInter1873",
"DDInter762"
] | Trimethobenzamide | Flurazepam | Trimethobenzamide is a novel antiemetic which prevents nausea and vomiting in humans. Its actions are unclear but most likely involves the chemoreceptor trigger zone (CTZ). In dogs pretreated with trimethobenzamide HCl, the emetic response to apomorphine is inhibited, while little or no protection is afforded against e... | A benzodiazepine derivative used mainly as a hypnotic. | Moderate | 1 | [
[
[
717,
24,
1216
]
],
[
[
717,
24,
1418
],
[
1418,
1,
1216
]
],
[
[
717,
24,
481
],
[
481,
40,
1216
]
],
[
[
717,
63,
216
],
[
216,
... | [
[
[
"Trimethobenzamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Flurazepam"
]
],
[
[
"Trimethobenzamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Estazolam"
... | Trimethobenzamide may cause a moderate interaction that could exacerbate diseases when taken with Estazolam and Estazolam (Compound) resembles Flurazepam (Compound)
Trimethobenzamide may cause a moderate interaction that could exacerbate diseases when taken with Quazepam and Quazepam (Compound) resembles Flurazepam (Co... |
DB01229 | DB01265 | 973 | 1,477 | [
"DDInter1377",
"DDInter1757"
] | Paclitaxel | Telbivudine | Paclitaxel is a chemotherapeutic agent marketed under the brand name Taxol among others. Used as a treatment for various cancers, paclitaxel is a mitotic inhibitor that was first isolated in 1971 from the bark of the Pacific yew tree which contains endophytic fungi that synthesize paclitaxel. It is available as an intr... | Telbivudine is a synthetic thymidine nucleoside analog with specific activity against the hepatitis B virus. Telbivudine is orally administered, with good tolerance, lack of toxicity and no dose-limiting side effects. | Moderate | 1 | [
[
[
973,
24,
1477
]
],
[
[
973,
63,
139
],
[
139,
1,
1477
]
],
[
[
973,
21,
28745
],
[
28745,
60,
1477
]
],
[
[
973,
63,
112
],
[
112,
... | [
[
[
"Paclitaxel",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Telbivudine"
]
],
[
[
"Paclitaxel",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Zidovudine"
],
[
... | Paclitaxel may cause a moderate interaction that could exacerbate diseases when taken with Zidovudine and Zidovudine (Compound) resembles Telbivudine (Compound)
Paclitaxel (Compound) causes Neuropathy peripheral (Side Effect) and Neuropathy peripheral (Side Effect) is caused by Telbivudine (Compound)
Paclitaxel may cau... |
DB00661 | DB05239 | 122 | 866 | [
"DDInter1928",
"DDInter425"
] | Verapamil | Cobimetinib | Verapamil is a phenylalkylamine calcium channel blocker used in the treatment of high blood pressure, heart arrhythmias, and angina, and was the first calcium channel antagonist to be introduced into therapy in the early 1960s. It is a member of the non-dihydropyridine class of calcium channel blockers, which includes ... | Cobimetinib is an orally active, potent and highly selective small molecule inhibiting mitogen-activated protein kinase kinase 1 (MAP2K1 or MEK1), and central components of the RAS/RAF/MEK/ERK signal transduction pathway. It has been approved in Switzerland and the US, in combination with vemurafenib for the treatment ... | Major | 2 | [
[
[
122,
25,
866
]
],
[
[
122,
24,
214
],
[
214,
63,
866
]
],
[
[
122,
25,
1478
],
[
1478,
63,
866
]
],
[
[
122,
62,
1101
],
[
1101,
... | [
[
[
"Verapamil",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Cobimetinib"
]
],
[
[
"Verapamil",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fostamatinib"
],
[
"Fostamati... | Verapamil may cause a moderate interaction that could exacerbate diseases when taken with Fostamatinib and Fostamatinib may cause a moderate interaction that could exacerbate diseases when taken with Cobimetinib
Verapamil may lead to a major life threatening interaction when taken with Ivacaftor and Ivacaftor may cause... |
DB01377 | DB01589 | 1,283 | 481 | [
"DDInter1119",
"DDInter1552"
] | Magnesium oxide | Quazepam | Magnesium oxide is an inorganic compound that occurs in nature as the mineral periclase. In aqueous media combines quickly with water to form magnesium hydroxide. It is used as an antacid and mild laxative and has many nonmedicinal uses. | Quazepam is a trifluoroethyl benzodiazepine derivative. It was first approved in the US in 1985 and is used as a hypnotic for the treatment of insomnia. It appears to be unique amongst other benzodiazepine derivatives in its relatively high affinity for sleep-promoting α1 subunit-containing GABA<sub>A</sub> receptors a... | Minor | 0 | [
[
[
1283,
23,
481
]
],
[
[
1283,
62,
1216
],
[
1216,
1,
481
]
],
[
[
1283,
62,
905
],
[
905,
40,
481
]
],
[
[
1283,
24,
286
],
[
286,
... | [
[
[
"Magnesium oxide",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Quazepam"
]
],
[
[
"Magnesium oxide",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Flurazepam"
],
... | Magnesium oxide may cause a minor interaction that can limit clinical effects when taken with Flurazepam and Flurazepam (Compound) resembles Quazepam (Compound)
Magnesium oxide may cause a minor interaction that can limit clinical effects when taken with Lorazepam and Lorazepam (Compound) resembles Quazepam (Compound)
... |
DB00346 | DB08820 | 472 | 1,478 | [
"DDInter44",
"DDInter997"
] | Alfuzosin | Ivacaftor | Benign prostatic hyperplasia (BPH) refers to a benign growth or hyperplasia of the prostate and leads to lower urinary tract symptoms in men, such as urgency, frequency and changes to urine flow. The prevalence of BPH is as high as 50%-60% for males in their 60's, and this prevalence increases to 80%-90% of those over ... | Ivacaftor (also known as Kalydeco or VX-770) is a drug used for the management of Cystic Fibrosis (CF). It is manufactured and distributed by Vertex Pharmaceuticals. It was approved by the Food and Drug Administration on January 31, 2012, and by Health Canada in late 2012. Ivacaftor is administered as a monotherapy and... | Moderate | 1 | [
[
[
472,
24,
1478
]
],
[
[
472,
6,
8374
],
[
8374,
45,
1478
]
],
[
[
472,
21,
29221
],
[
29221,
60,
1478
]
],
[
[
472,
24,
543
],
[
543,
... | [
[
[
"Alfuzosin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ivacaftor"
]
],
[
[
"Alfuzosin",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)",
... | Alfuzosin (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Ivacaftor (Compound)
Alfuzosin (Compound) causes Infestation (Side Effect) and Infestation (Side Effect) is caused by Ivacaftor (Compound)
Alfuzosin may cause a moderate interaction that could exacerbate diseases when taken with Loperamide and Loper... |
DB09570 | DB10429 | 1,480 | 200 | [
"DDInter1002",
"DDInter282"
] | Ixazomib | Candida albicans | Ixazomib a second generation proteasome inhibitor (PI) and the first oral PI approved by the FDA in November 2015 for multiple myeloma treatment in combination with 2 other therapies (lenalidomide and dexamethasone) for patients who have received at least 1 prior therapy. It was found to have similar efficacy to bortez... | Candida albicans is a fungus which can provoke allergic reactions. Candida albicans is used in allergenic testing. | Moderate | 1 | [
[
[
1480,
24,
200
]
],
[
[
1480,
63,
1683
],
[
1683,
24,
200
]
],
[
[
1480,
64,
976
],
[
976,
24,
200
]
],
[
[
1480,
24,
738
],
[
738,
... | [
[
[
"Ixazomib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Candida albicans"
]
],
[
[
"Ixazomib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ustekinumab"
],
[... | Ixazomib may cause a moderate interaction that could exacerbate diseases when taken with Ustekinumab and Ustekinumab may cause a moderate interaction that could exacerbate diseases when taken with Candida albicans
Ixazomib may lead to a major life threatening interaction when taken with Tofacitinib and Tofacitinib may ... |
DB01333 | DB09268 | 207 | 1,662 | [
"DDInter328",
"DDInter1464"
] | Cefradine | Picosulfuric acid | A semi-synthetic cephalosporin antibiotic. | Picosulfuric acid is found in laxative products. Sodium picosulfate is a used to treat constipation or induce colon cleansing to prepare the large bowels before colonoscopy or surgery. The combination product containing sodium picosulfate and magnesium citrate was introduced to the Canadian market in 2005 and has been ... | Moderate | 1 | [
[
[
207,
24,
1662
]
],
[
[
207,
63,
597
],
[
597,
24,
1662
]
],
[
[
207,
1,
319
],
[
319,
24,
1662
]
],
[
[
207,
40,
1124
],
[
1124,
... | [
[
[
"Cefradine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Picosulfuric acid"
]
],
[
[
"Cefradine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Chloramphenicol"
]... | Cefradine may cause a moderate interaction that could exacerbate diseases when taken with Chloramphenicol and Chloramphenicol may cause a moderate interaction that could exacerbate diseases when taken with Picosulfuric acid
Cefradine (Compound) resembles Amoxicillin (Compound) and Amoxicillin may cause a moderate inter... |
DB00031 | DB00476 | 20 | 109 | [
"DDInter1764",
"DDInter608"
] | Tenecteplase | Duloxetine | Tenecteplase is a tissue plasminogen activator (tPA) developed from modifications of natural human tPA complementary DNA (cDNA). It is a 527 amino acid with a substitution of threonine 103 with asparagine and substitution of asparagine 117 with glutamine within the kringle 1 domain, and a tetra-alanine substitution at ... | Duloxetine is a dual serotonin and norepinephrine reuptake inhibitor.[label] It was originally discovered in 1993 and developed by Eli Lilly and Company as LY248686. Duloxetine first received approval from the FDA in August, 2004 as Cymbalta for the treatment of Major Depressive Disorder. It has since received approval... | Moderate | 1 | [
[
[
20,
24,
109
]
],
[
[
20,
24,
758
],
[
758,
1,
109
]
],
[
[
20,
25,
1409
],
[
1409,
63,
109
]
],
[
[
20,
25,
273
],
[
273,
24,
... | [
[
[
"Tenecteplase",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Duloxetine"
]
],
[
[
"Tenecteplase",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fluoxetine"
],
... | Tenecteplase may cause a moderate interaction that could exacerbate diseases when taken with Fluoxetine and Fluoxetine (Compound) resembles Duloxetine (Compound)
Tenecteplase may lead to a major life threatening interaction when taken with Apixaban and Apixaban may cause a moderate interaction that could exacerbate dis... |
DB00214 | DB08881 | 1,028 | 868 | [
"DDInter1836",
"DDInter1925"
] | Torasemide | Vemurafenib | Torasemide is a high-ceiling loop diuretic. Structurally, it is a pyridine-sulfonylurea used as an antihypertensive agent. Torasemide was first approved for clinical use by the FDA in 1993. | Vemurafenib is a competitive kinase inhibitor with activity against BRAF kinase with mutations like V600E. It exerts its function by binding to the ATP-binding domain of the mutant BRAF. Vemurafenib was co-developed by Roche and Plexxikon and it obtained its FDA approval on August 17, 2011, under the company Hoffmann L... | Moderate | 1 | [
[
[
1028,
24,
868
]
],
[
[
1028,
18,
17469
],
[
17469,
57,
868
]
],
[
[
1028,
21,
29106
],
[
29106,
60,
868
]
],
[
[
1028,
24,
112
],
[
11... | [
[
[
"Torasemide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Vemurafenib"
]
],
[
[
"Torasemide",
"{u} (Compound) downregulates {v} (Gene)",
"ADI1"
],
[
"ADI1",
"{u} (Gene) is downregulated by {v}... | Torasemide (Compound) downregulates ADI1 (Gene) and ADI1 (Gene) is downregulated by Vemurafenib (Compound)
Torasemide (Compound) causes Myalgia (Side Effect) and Myalgia (Side Effect) is caused by Vemurafenib (Compound)
Torasemide may cause a moderate interaction that could exacerbate diseases when taken with Metronida... |
DB00486 | DB01114 | 1,614 | 272 | [
"DDInter1253",
"DDInter362"
] | Nabilone | Chlorpheniramine | Nabilone (marketed as Cesamet) is a synthetic form of delta-9-tetrahydrocannabinol (Δ⁹-THC), the primary psychoactive component of cannabis (marijuana). Although structurally distinct from THC, nabilone mimics THC's structure and pharmacological activity through weak partial agonist activity at Cannabinoid-1 (CB1R) and... | A histamine H1 antagonist used in allergic reactions, hay fever, rhinitis, urticaria, and asthma. It has also been used in veterinary applications. One of the most widely used of the classical antihistaminics, it generally causes less drowsiness and sedation than promethazine. | Moderate | 1 | [
[
[
1614,
24,
272
]
],
[
[
1614,
24,
358
],
[
358,
63,
272
]
],
[
[
1614,
63,
128
],
[
128,
24,
272
]
],
[
[
1614,
21,
28705
],
[
28705,
... | [
[
[
"Nabilone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Chlorpheniramine"
]
],
[
[
"Nabilone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Orphenadrine"
],
... | Nabilone may cause a moderate interaction that could exacerbate diseases when taken with Orphenadrine and Orphenadrine may cause a moderate interaction that could exacerbate diseases when taken with Chlorpheniramine
Nabilone may cause a moderate interaction that could exacerbate diseases when taken with Dexbrompheniram... |
DB00834 | DB09143 | 932 | 313 | [
"DDInter1215",
"DDInter1701"
] | Mifepristone | Sonidegib | Mifepristone is a progestational and glucocorticoid hormone antagonist. Its inhibition of progesterone induces bleeding during the luteal phase and in early pregnancy by releasing endogenous prostaglandins from the endometrium or decidua. As a glucocorticoid receptor antagonist, the drug has been used to treat hypercor... | Sonidegib is a Hedgehog signaling pathway inhibitor (via smoothened antagonism) developed as an anticancer agent by Novartis. It was FDA approved in 2015 for the treatment of basal cell carcinoma. | Moderate | 1 | [
[
[
932,
24,
313
]
],
[
[
932,
24,
1559
],
[
1559,
23,
313
]
],
[
[
932,
25,
478
],
[
478,
24,
313
]
],
[
[
932,
24,
1478
],
[
1478,
... | [
[
[
"Mifepristone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sonidegib"
]
],
[
[
"Mifepristone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Famotidine"
],
[... | Mifepristone may cause a moderate interaction that could exacerbate diseases when taken with Famotidine and Famotidine may cause a minor interaction that can limit clinical effects when taken with Sonidegib
Mifepristone may lead to a major life threatening interaction when taken with Nilotinib and Nilotinib may cause a... |
DB00999 | DB06335 | 504 | 761 | [
"DDInter883",
"DDInter1646"
] | Hydrochlorothiazide | Saxagliptin | Hydrochlorothiazide is the most commonly prescribed thiazide diuretic. It is indicated to treat edema and hypertension.[A185138,L8447,L8450] Hydrochlorothiazide use is common but declining in favour of angiotensin converting enzyme inhibitors. Many combination products are available containing hydrochlorothiazide and a... | Saxagliptin (rINN) is an orally active hypoglycemic (anti-diabetic drug) of the new dipeptidyl peptidase-4 (DPP-4) inhibitor class of drugs. FDA approved on July 31, 2009. | Moderate | 1 | [
[
[
504,
24,
761
]
],
[
[
504,
21,
28966
],
[
28966,
60,
761
]
],
[
[
504,
1,
1577
],
[
1577,
24,
761
]
],
[
[
504,
63,
104
],
[
104,
... | [
[
[
"Hydrochlorothiazide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Saxagliptin"
]
],
[
[
"Hydrochlorothiazide",
"{u} (Compound) causes {v} (Side Effect)",
"Upper respiratory tract infection"
],
[
"U... | Hydrochlorothiazide (Compound) causes Upper respiratory tract infection (Side Effect) and Upper respiratory tract infection (Side Effect) is caused by Saxagliptin (Compound)
Hydrochlorothiazide (Compound) resembles Hydroflumethiazide (Compound) and Hydroflumethiazide may cause a moderate interaction that could exacerba... |
DB00188 | DB08901 | 168 | 1,468 | [
"DDInter222",
"DDInter1492"
] | Bortezomib | Ponatinib | Bortezomib is a dipeptide boronic acid derivative and proteasome inhibitor used to treat multiple myeloma and mantle cell lymphoma. The 26S proteasome is a protein complex that degrades ubiquitinated proteins in the ubiquitin-proteasome pathway: reversible inhibition of the 26S proteasome, leading to cell cycle arrest ... | Ponatinib is a novel Bcr-Abl tyrosine kinase inhibitor that is especially effective against the T315I mutation for the treatment of chronic myeloid leukemia. FDA approved on December 14, 2012. | Moderate | 1 | [
[
[
168,
24,
1468
]
],
[
[
168,
24,
478
],
[
478,
24,
1468
]
],
[
[
168,
6,
12523
],
[
12523,
45,
1468
]
],
[
[
168,
7,
7580
],
[
7580,
... | [
[
[
"Bortezomib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ponatinib"
]
],
[
[
"Bortezomib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Nilotinib"
],
[
... | Bortezomib may cause a moderate interaction that could exacerbate diseases when taken with Nilotinib and Nilotinib may cause a moderate interaction that could exacerbate diseases when taken with Ponatinib
Bortezomib (Compound) binds CYP2D6 (Gene) and CYP2D6 (Gene) is bound by Ponatinib (Compound)
Bortezomib (Compound) ... |
DB00489 | DB00747 | 17 | 1,442 | [
"DDInter1704",
"DDInter1647"
] | Sotalol | Scopolamine | Sotalol is a methanesulfonanilide developed in 1960. It was the first of the class III anti arrhythmic drugs. Sotalol was first approved as an oral tablet on 30 October 1992. A racemic mixture of sotalol is currently formulated as a tablet, oral solution, and intravenous injection indicated for life threatening ventric... | Scopolamine is a tropane alkaloid isolated from members of the _Solanaceae_ family of plants, similar to [atropine] and [hyoscyamine], all of which structurally mimic the natural neurotransmitter [acetylcholine].[A228423, A228763] Scopolamine was first synthesized in 1959, but to date, synthesis remains less efficient ... | Moderate | 1 | [
[
[
17,
24,
1442
]
],
[
[
17,
63,
19
],
[
19,
24,
1442
]
],
[
[
17,
21,
29326
],
[
29326,
60,
1442
]
],
[
[
17,
24,
543
],
[
543,
63... | [
[
[
"Sotalol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Scopolamine"
]
],
[
[
"Sotalol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Hyoscyamine"
],
[
... | Sotalol may cause a moderate interaction that could exacerbate diseases when taken with Hyoscyamine and Hyoscyamine may cause a moderate interaction that could exacerbate diseases when taken with Scopolamine
Sotalol (Compound) causes Photophobia (Side Effect) and Photophobia (Side Effect) is caused by Scopolamine (Comp... |
DB01244 | DB04868 | 762 | 478 | [
"DDInter192",
"DDInter1293"
] | Bepridil | Nilotinib | A long-acting, non selective, calcium channel blocker with significant anti-anginal activity. The drug produces significant coronary vasodilation and modest peripheral effects. It has antihypertensive and selective anti-arrhythmia activities and acts as a calmodulin antagonist. It is no longer marketed in the United St... | Nilotinib, also known as AMN107, is a tyrosine kinase inhibitor under investigation as a possible treatment for chronic myelogenous leukemia (CML). A Phase I clinical trial in 2006 showed that this drug was relatively safe and offered significant therapeutic benefits in cases of CML which were found to be resistant to ... | Major | 2 | [
[
[
762,
25,
478
]
],
[
[
762,
6,
4973
],
[
4973,
45,
478
]
],
[
[
762,
21,
28963
],
[
28963,
60,
478
]
],
[
[
762,
23,
1135
],
[
1135,
... | [
[
[
"Bepridil",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Nilotinib"
]
],
[
[
"Bepridil",
"{u} (Compound) binds {v} (Gene)",
"ABCB1"
],
[
"ABCB1",
"{u} (Gene) is bound by {v} (Compound)",
"Nilotinib"
... | Bepridil (Compound) binds ABCB1 (Gene) and ABCB1 (Gene) is bound by Nilotinib (Compound)
Bepridil (Compound) causes Anxiety (Side Effect) and Anxiety (Side Effect) is caused by Nilotinib (Compound)
Bepridil may cause a minor interaction that can limit clinical effects when taken with Naloxegol and Naloxegol may cause a... |
DB01036 | DB01176 | 211 | 537 | [
"DDInter1832",
"DDInter453"
] | Tolterodine | Cyclizine | Tolterodine is an antimuscarinic drug that is used to treat urinary incontinence. Tolterodine acts on M2 and M3 subtypes of muscarinic receptors. | A histamine H1 antagonist given by mouth or parenterally for the control of postoperative and drug-induced vomiting and in motion sickness. (From Martindale, The Extra Pharmacopoeia, 30th ed, p935) | Moderate | 1 | [
[
[
211,
24,
537
]
],
[
[
211,
24,
1511
],
[
1511,
63,
537
]
],
[
[
211,
40,
11244
],
[
11244,
1,
537
]
],
[
[
211,
63,
104
],
[
104,
... | [
[
[
"Tolterodine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cyclizine"
]
],
[
[
"Tolterodine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Mepenzolate"
],
[
... | Tolterodine may cause a moderate interaction that could exacerbate diseases when taken with Mepenzolate and Mepenzolate may cause a moderate interaction that could exacerbate diseases when taken with Cyclizine
Tolterodine (Compound) resembles Pheniramine (Compound) and Pheniramine (Compound) resembles Cyclizine (Compou... |
DB00252 | DB00758 | 362 | 1,347 | [
"DDInter1460",
"DDInter413"
] | Phenytoin | Clopidogrel | Phenytoin is classified as a hydantoin derivative and despite its narrow therapeutic index, it is one of the most commonly used anticonvulsants.[A33595,A188832,A189219] Since it's introduction about 80 years ago, phenytoin has not only been established as an effective anti-epileptic, but has also been investigated for ... | Clopidogrel is a prodrug of a platelet inhibitor used to reduce the risk of myocardial infarction and stroke.[A180508,L7213] Clopidogrel is indicated to reduce the risk of myocardial infarction for patients with non-ST elevated acute coronary syndrome (ACS), patients with ST-elevated myocardial infarction, and in recen... | Minor | 0 | [
[
[
362,
23,
1347
]
],
[
[
362,
63,
1018
],
[
1018,
25,
1347
]
],
[
[
362,
6,
7603
],
[
7603,
45,
1347
]
],
[
[
362,
21,
28744
],
[
28744,... | [
[
[
"Phenytoin",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Clopidogrel"
]
],
[
[
"Phenytoin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ticlopidine"
],
[
... | Phenytoin may cause a moderate interaction that could exacerbate diseases when taken with Ticlopidine and Ticlopidine may lead to a major life threatening interaction when taken with Clopidogrel
Phenytoin (Compound) binds CYP2B6 (Gene) and CYP2B6 (Gene) is bound by Clopidogrel (Compound)
Phenytoin (Compound) causes Dea... |
DB00023 | DB00879 | 305 | 1,279 | [
"DDInter127",
"DDInter637"
] | Asparaginase Escherichia coli | Emtricitabine | Asparaginase derived from _Escherichia coli_ (L-asparagine amidohydrolase, EC 3.5.1.1) is an enzyme responsible for the metabolism of L-asparagine, by catalyzing L-asparagine into L-aspartic acid and ammonia. It also facilitates the production of oxaloacetate which is needed for general cellular metabolism. Asparaginas... | Emtricitabine is a nucleoside reverse transcriptase inhibitor (NRTI) indicated for the treatment of HIV infection in adults or combined with [tenofovir alafenamide] for the prevention of HIV-1 infection in high risk adolescents and adults. Emtricitabine is a cytidine analogue. The drug works by inhibiting HIV reverse t... | Moderate | 1 | [
[
[
305,
24,
1279
]
],
[
[
305,
24,
322
],
[
322,
24,
1279
]
],
[
[
305,
24,
384
],
[
384,
63,
1279
]
],
[
[
305,
25,
1064
],
[
1064,
... | [
[
[
"Asparaginase Escherichia coli",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Emtricitabine"
]
],
[
[
"Asparaginase Escherichia coli",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with... | Asparaginase Escherichia coli may cause a moderate interaction that could exacerbate diseases when taken with Epirubicin and Epirubicin may cause a moderate interaction that could exacerbate diseases when taken with Emtricitabine
Asparaginase Escherichia coli may cause a moderate interaction that could exacerbate disea... |
DB03619 | DB08896 | 557 | 292 | [
"DDInter501",
"DDInter1576"
] | Deoxycholic acid | Regorafenib | Deoxycholic acid is a a bile acid which emulsifies and solubilizes dietary fats in the intestine, and when injected subcutaneously, it disrupts cell membranes in adipocytes and destroys fat cells in that tissue. In April 2015, deoxycholic acid was approved by the FDA for the treatment submental fat to improve aesthetic... | Regorafenib is an orally-administered inhibitor of multiple kinases. It is used for the treatment of metastatic colorectal cancer, advanced gastrointestinal stromal tumours, and hepatocellular carcinoma. FDA approved on September 27, 2012. Approved use of Regorafenib was expanded to treat Hepatocellular Carcinoma in Ap... | Moderate | 1 | [
[
[
557,
24,
292
]
],
[
[
557,
24,
1040
],
[
1040,
63,
292
]
],
[
[
557,
63,
553
],
[
553,
25,
292
]
],
[
[
557,
24,
792
],
[
792,
2... | [
[
[
"Deoxycholic acid",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Regorafenib"
]
],
[
[
"Deoxycholic acid",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dabrafenib"
... | Deoxycholic acid may cause a moderate interaction that could exacerbate diseases when taken with Dabrafenib and Dabrafenib may cause a moderate interaction that could exacerbate diseases when taken with Regorafenib
Deoxycholic acid may cause a moderate interaction that could exacerbate diseases when taken with Fondapar... |
DB11652 | DB12141 | 1,155 | 971 | [
"DDInter1891",
"DDInter817"
] | Tucatinib | Gilteritinib | Tucatinib is a kinase inhibitor drug used with [trastuzumab] and [capecitabine] in the treatment of unresectable or metastatic HER-2 positive breast cancer. It was developed by Seattle Genetics and approved by the FDA on April 17, 2020. Tucatinib is a promising new treatment for patients with metastatic breast cancer w... | Gilteritinib, also known as ASP2215, is a small molecule part of the FLT3 tyrosine kinase inhibitors that presented a greater selectivity and potency when compared with other agents from this group. It is a pyrazinecarboxamide derivative that showed high selectivity to FLT3 preventing the c-Kit -driven myelosuppression... | Major | 2 | [
[
[
1155,
25,
971
]
],
[
[
1155,
64,
1135
],
[
1135,
23,
971
]
],
[
[
1155,
24,
466
],
[
466,
62,
971
]
],
[
[
1155,
63,
72
],
[
72,
... | [
[
[
"Tucatinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Gilteritinib"
]
],
[
[
"Tucatinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Naloxegol"
],
[
"Naloxegol",
"{u} may... | Tucatinib may lead to a major life threatening interaction when taken with Naloxegol and Naloxegol may cause a minor interaction that can limit clinical effects when taken with Gilteritinib
Tucatinib may cause a moderate interaction that could exacerbate diseases when taken with Darolutamide and Darolutamide may cause ... |
DB00330 | DB00446 | 238 | 597 | [
"DDInter689",
"DDInter351"
] | Ethambutol | Chloramphenicol | Ethambutol is a bacteriostatic agent indicated alongside medications such as [isoniazid], [rifampin], and [pyrazinamide] in the treatment of pulmonary tuberculosis. Ethambutol was first described in the literature in 1961. It was developed out of a need for therapies active against isoniazid resistant strains of _Mycob... | An antibiotic first isolated from cultures of _Streptomyces venezuelae_ in 1947 but now produced synthetically. It has a relatively simple structure and was the first broad-spectrum antibiotic to be discovered. It acts by interfering with bacterial protein synthesis and is mainly bacteriostatic. (From Martindale, The E... | Moderate | 1 | [
[
[
238,
24,
597
]
],
[
[
238,
21,
28787
],
[
28787,
60,
597
]
],
[
[
238,
24,
1626
],
[
1626,
63,
597
]
],
[
[
238,
63,
367
],
[
367,
... | [
[
[
"Ethambutol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Chloramphenicol"
]
],
[
[
"Ethambutol",
"{u} (Compound) causes {v} (Side Effect)",
"Dermatitis"
],
[
"Dermatitis",
"{u} (Side Effect) ... | Ethambutol (Compound) causes Dermatitis (Side Effect) and Dermatitis (Side Effect) is caused by Chloramphenicol (Compound)
Ethambutol may cause a moderate interaction that could exacerbate diseases when taken with Elotuzumab and Elotuzumab may cause a moderate interaction that could exacerbate diseases when taken with ... |
DB00208 | DB06754 | 1,018 | 707 | [
"DDInter1804",
"DDInter471"
] | Ticlopidine | Danaparoid | Ticlopidine is an effective inhibitor of platelet aggregation. It is a prodrug that is metabolised to an active form, which blocks the ADP receptor that is involved in GPIIb/IIIa receptor activation leading to platelet aggregation. Ticlopidine is marketed under the brand name Ticlid and is indicated for patients who ca... | Danaparoid is a low-molecular-weight heparinoid with an average molecular weight of 5500 Daltons consisting of a mixture of glycosaminoglycans . The active constituents are heparan, dermatan and , and they are isolated from the porcine intestinal mucosa [FDA Label]. Danaparoid possesses a potent antithrombic activity t... | Major | 2 | [
[
[
1018,
25,
707
]
],
[
[
1018,
23,
944
],
[
944,
62,
707
]
],
[
[
1018,
24,
1496
],
[
1496,
63,
707
]
],
[
[
1018,
24,
901
],
[
901,
... | [
[
[
"Ticlopidine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Danaparoid"
]
],
[
[
"Ticlopidine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Chamomile"
],
[
"Chamomile",... | Ticlopidine may cause a minor interaction that can limit clinical effects when taken with Chamomile and Chamomile may cause a minor interaction that can limit clinical effects when taken with Danaparoid
Ticlopidine may cause a moderate interaction that could exacerbate diseases when taken with Nintedanib and Nintedanib... |
DB00035 | DB00370 | 1,314 | 1,251 | [
"DDInter507",
"DDInter1230"
] | Desmopressin | Mirtazapine | Desmopressin (dDAVP), a synthetic analogue of 8-arginine vasopressin (ADH), is an antidiuretic peptide drug modified by deamination of 1-cysteine and substitution of 8-L-arginine by 8-D-arginine. ADH is an endogenous pituitary hormone that has a crucial role in the control of the water content in the body. Upon release... | Mirtazapine is a tetracyclic _piperazino-azepine_ antidepressant agent that was initially approved for the treatment of major depressive disorder (MDD) in the Netherlands in 1994. This drug was first manufactured by Organon Inc., and received FDA approval in 1997 for the treatment of major depressive disorder.[T595, L6... | Moderate | 1 | [
[
[
1314,
24,
1251
]
],
[
[
1314,
21,
28680
],
[
28680,
60,
1251
]
],
[
[
1314,
24,
1148
],
[
1148,
63,
1251
]
],
[
[
1314,
25,
1220
],
[
... | [
[
[
"Desmopressin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Mirtazapine"
]
],
[
[
"Desmopressin",
"{u} (Compound) causes {v} (Side Effect)",
"Rash"
],
[
"Rash",
"{u} (Side Effect) is caused by... | Desmopressin (Compound) causes Rash (Side Effect) and Rash (Side Effect) is caused by Mirtazapine (Compound)
Desmopressin may cause a moderate interaction that could exacerbate diseases when taken with Isoprenaline and Isoprenaline may cause a moderate interaction that could exacerbate diseases when taken with Mirtazap... |
DB00939 | DB12364 | 1,338 | 1,421 | [
"DDInter1135",
"DDInter200"
] | Meclofenamic acid | Betrixaban | A non-steroidal anti-inflammatory agent with antipyretic and antigranulation activities. It also inhibits prostaglandin biosynthesis. | Betrixaban is a non-vitamin K oral anticoagulant whose action is driven by the competitive and reversible inhibition of the factor Xa . It was selected among all lead compounds due to its low hERG channel affinity while sustaining its factor Xa inhibition capacity . Betrixaban, now developed by Portola Pharmaceuticals ... | Major | 2 | [
[
[
1338,
25,
1421
]
],
[
[
1338,
24,
1039
],
[
1039,
24,
1421
]
],
[
[
1338,
63,
305
],
[
305,
24,
1421
]
],
[
[
1338,
24,
714
],
[
714,
... | [
[
[
"Meclofenamic acid",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Betrixaban"
]
],
[
[
"Meclofenamic acid",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dexfenfluramine"
],
... | Meclofenamic acid may cause a moderate interaction that could exacerbate diseases when taken with Dexfenfluramine and Dexfenfluramine may cause a moderate interaction that could exacerbate diseases when taken with Betrixaban
Meclofenamic acid may cause a moderate interaction that could exacerbate diseases when taken wi... |
DB09104 | DB12035 | 286 | 943 | [
"DDInter1118",
"DDInter1641"
] | Magnesium hydroxide | Sarecycline | Magnesium hydroxide is an inorganic compound. It is naturally found as the mineral brucite. Magnesium hydroxide can be used as an antacid or a laxative in either an oral liquid suspension or chewable tablet form. Additionally, magnesium hydroxide has smoke suppressing and flame retardant properties and is thus used com... | Sarecycline is a semi-synthetic derivative of tetracycline that was initially discovered by Paratek Pharmaceuticals from Boston, MA but then licensed to Warner Chilcott of Rockaway, NJ in July of 2007 . After completing various phase-II and phase-III trials demonstrating its effectiveness in treating moderate to severe... | Moderate | 1 | [
[
[
286,
24,
943
]
],
[
[
286,
63,
1181
],
[
1181,
24,
943
]
],
[
[
286,
24,
460
],
[
460,
24,
943
]
],
[
[
286,
24,
971
],
[
971,
6... | [
[
[
"Magnesium hydroxide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sarecycline"
]
],
[
[
"Magnesium hydroxide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Terfenad... | Magnesium hydroxide may cause a moderate interaction that could exacerbate diseases when taken with Terfenadine and Terfenadine may cause a moderate interaction that could exacerbate diseases when taken with Sarecycline
Magnesium hydroxide may cause a moderate interaction that could exacerbate diseases when taken with ... |
DB08865 | DB09343 | 1,593 | 750 | [
"DDInter448",
"DDInter1816"
] | Crizotinib | Tipiracil | Crizotinib is a tyrosine kinase receptor inhibitor used for the treatment of anaplastic lymphoma kinase (ALK) or ROS1-positive non-small cell lung cancer (NSCLC) tumors, as well as ALK-positive anaplastic large cell lymphoma (ALCL) and inflammatory myofibroblastic tumor (IMT). By targeting the echinoderm microtubule-as... | Tipiracil is a thymidine phosphorylase inhibitor. It is used in combination with trifluridine, in a ratio of 1:0.5, to form TAS-102. The main function of Tipiracil in TAS-102 is to increase trifluridine bioavailability by inhibiting its catabolism. TAS-102 is indicated for the treatment of metastatic colorectal cancer ... | Moderate | 1 | [
[
[
1593,
24,
750
]
],
[
[
1593,
25,
1228
],
[
1228,
24,
750
]
],
[
[
1593,
25,
1476
],
[
1476,
63,
750
]
],
[
[
1593,
64,
1069
],
[
1069,... | [
[
[
"Crizotinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tipiracil"
]
],
[
[
"Crizotinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Lenvatinib"
],
[
"Lenvatinib"... | Crizotinib may lead to a major life threatening interaction when taken with Lenvatinib and Lenvatinib may cause a moderate interaction that could exacerbate diseases when taken with Tipiracil
Crizotinib may lead to a major life threatening interaction when taken with Brigatinib and Brigatinib may cause a moderate inter... |
DB00745 | DB00912 | 307 | 473 | [
"DDInter1236",
"DDInter1581"
] | Modafinil | Repaglinide | Modafinil is a stimulant drug marketed as a 'wakefulness promoting agent' and is one of the stimulants used in the treatment of narcolepsy. Narcolepsy is caused by dysfunction of a family of wakefulness-promoting and sleep-suppressing peptides, the orexins, whose neurons are activated by modafinil. The prexin neuron ac... | Repaglinide is an oral antihyperglycemic agent used for the treatment of non-insulin-dependent diabetes mellitus (NIDDM). It belongs to the meglitinide class of short-acting insulin secretagogues, which act by binding to β cells of the pancreas to stimulate insulin release. Repaglinide induces an early insulin response... | Moderate | 1 | [
[
[
307,
24,
473
]
],
[
[
307,
6,
8374
],
[
8374,
45,
473
]
],
[
[
307,
21,
28763
],
[
28763,
60,
473
]
],
[
[
307,
23,
609
],
[
609,
... | [
[
[
"Modafinil",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Repaglinide"
]
],
[
[
"Modafinil",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)",
... | Modafinil (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Repaglinide (Compound)
Modafinil (Compound) causes Chest pain (Side Effect) and Chest pain (Side Effect) is caused by Repaglinide (Compound)
Modafinil may cause a minor interaction that can limit clinical effects when taken with Clarithromycin and C... |
DB00660 | DB09054 | 1,470 | 384 | [
"DDInter1163",
"DDInter905"
] | Metaxalone | Idelalisib | Metaxalone is a moderate to strong muscle relaxant used in the symptomatic treatment of musculoskeletal pain caused by strains, sprains, and other musculoskeletal conditions. It is marketed by King Pharmaceuticals under the brand name Skelaxin®. Its main mechanism of action is thought to involve general central nervous... | Idelalisib is a phosphoinositide 3-kinase inhibitor indicated in the treatment of chronic lymphocytic leukemia (CLL), relapsed follicular B-cell non-Hodgkin lymphoma (FL), and relapsed small lymphocytic lymphoma (SLL). For the treatment of relapsed CLL, it is currently indicated as a second-line agent in combination wi... | Moderate | 1 | [
[
[
1470,
24,
384
]
],
[
[
1470,
24,
222
],
[
222,
23,
384
]
],
[
[
1470,
63,
305
],
[
305,
24,
384
]
],
[
[
1470,
24,
267
],
[
267,
... | [
[
[
"Metaxalone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Idelalisib"
]
],
[
[
"Metaxalone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sibutramine"
],
[
... | Metaxalone may cause a moderate interaction that could exacerbate diseases when taken with Sibutramine and Sibutramine may cause a minor interaction that can limit clinical effects when taken with Idelalisib
Metaxalone may cause a moderate interaction that could exacerbate diseases when taken with Asparaginase Escheric... |
DB00358 | DB00661 | 1,010 | 122 | [
"DDInter1140",
"DDInter1928"
] | Mefloquine | Verapamil | Malaria is a protozoan disease that places an enormous burden on human health in endemic areas around the world. The 2020 World Health Organization malaria report indicates a 60% decrease in the global malaria fatality rate between 2000 to 2019. Despite this, malaria remains a significant cause of morbidity and mortali... | Verapamil is a phenylalkylamine calcium channel blocker used in the treatment of high blood pressure, heart arrhythmias, and angina, and was the first calcium channel antagonist to be introduced into therapy in the early 1960s. It is a member of the non-dihydropyridine class of calcium channel blockers, which includes ... | Moderate | 1 | [
[
[
1010,
24,
122
]
],
[
[
1010,
6,
12523
],
[
12523,
45,
122
]
],
[
[
1010,
21,
28809
],
[
28809,
60,
122
]
],
[
[
1010,
24,
36
],
[
36,
... | [
[
[
"Mefloquine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Verapamil"
]
],
[
[
"Mefloquine",
"{u} (Compound) binds {v} (Gene)",
"CYP2D6"
],
[
"CYP2D6",
"{u} (Gene) is bound by {v} (Compound)",
... | Mefloquine (Compound) binds CYP2D6 (Gene) and CYP2D6 (Gene) is bound by Verapamil (Compound)
Mefloquine (Compound) causes Diarrhoea (Side Effect) and Diarrhoea (Side Effect) is caused by Verapamil (Compound)
Mefloquine may cause a moderate interaction that could exacerbate diseases when taken with Eribulin and Eribulin... |
DB00741 | DB01132 | 167 | 1,130 | [
"DDInter885",
"DDInter1472"
] | Hydrocortisone | Pioglitazone | Hydrocortisone, or cortisol, is a glucocorticoid secreted by the adrenal cortex. Hydrocortisone is used to treat immune, inflammatory, and neoplastic conditions.[L10529,L10532,L10535,L10538,L7772,L7321] It was discovered in the 1930s by Edward Kendall and named Compound F, or 17-hydroxycorticosterone. Hydrocortisone wa... | Pioglitazone is an antihyperglycemic used as an adjunct to diet, exercise, and other antidiabetic medications to manage type 2 diabetes mellitus.[L11416,L11419,L11422,L11425] It is administered as a racemic mixture, though there is no pharmacologic difference between the enantiomers and they appear to interconvert _in ... | Moderate | 1 | [
[
[
167,
24,
1130
]
],
[
[
167,
6,
3486
],
[
3486,
45,
1130
]
],
[
[
167,
7,
2475
],
[
2475,
57,
1130
]
],
[
[
167,
21,
28661
],
[
28661,
... | [
[
[
"Hydrocortisone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pioglitazone"
]
],
[
[
"Hydrocortisone",
"{u} (Compound) binds {v} (Gene)",
"CYP2C8"
],
[
"CYP2C8",
"{u} (Gene) is bound by {v} (C... | Hydrocortisone (Compound) binds CYP2C8 (Gene) and CYP2C8 (Gene) is bound by Pioglitazone (Compound)
Hydrocortisone (Compound) upregulates RGS2 (Gene) and RGS2 (Gene) is downregulated by Pioglitazone (Compound)
Hydrocortisone (Compound) causes Acute coronary syndrome (Side Effect) and Acute coronary syndrome (Side Effec... |
DB00471 | DB14840 | 201 | 861 | [
"DDInter1242",
"DDInter1601"
] | Montelukast | Ripretinib | Montelukast was first approved for clinical use by the US FDA in 1998 as Merck's brand name Singulair. The medication is a member of the leukotriene receptor antagonist (LTRA) category of drugs.[L6301,L6304,L6307,L6310,L6325,L6328,L6331] Although capable of demonstrating effectiveness, the use of such LTRAs like montel... | Ripretinib is a kinase inhibitor used for the treatment of advanced gastrointestinal stromal tumor (GIST) that has not adequately responded to other kinase inhibitors such as [sunitinib] and [imatinib]. Ripretinib, also known as Qinlock, is manufactured by Deciphera Pharmaceuticals and was initially approved by the FDA... | Moderate | 1 | [
[
[
201,
24,
861
]
],
[
[
201,
24,
214
],
[
214,
24,
861
]
],
[
[
201,
63,
353
],
[
353,
24,
861
]
],
[
[
201,
24,
1604
],
[
1604,
2... | [
[
[
"Montelukast",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ripretinib"
]
],
[
[
"Montelukast",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fostamatinib"
],
... | Montelukast may cause a moderate interaction that could exacerbate diseases when taken with Fostamatinib and Fostamatinib may cause a moderate interaction that could exacerbate diseases when taken with Ripretinib
Montelukast may cause a moderate interaction that could exacerbate diseases when taken with Griseofulvin an... |
DB06176 | DB06288 | 1,342 | 607 | [
"DDInter1616",
"DDInter77"
] | Romidepsin | Amisulpride | Romidepsin is a selective inhibitor of histone deacetylase, approved in the US in 2009 for the treatment of cutaneous T-cell lymphoma (CTCL) in patients who have received at least one prior systemic therapy. | Amisulpride is a benzamide derivative and a dopamine receptor antagonist that selectively works on dopamine D2 and D3 receptors. As an antipsychotic agent, amisulpride alleviates both positive and negative symptoms of schizophrenia, and it exhibits antidepressant properties in patients with psychiatric disorders, dysth... | Major | 2 | [
[
[
1342,
25,
607
]
],
[
[
1342,
62,
112
],
[
112,
23,
607
]
],
[
[
1342,
63,
1559
],
[
1559,
24,
607
]
],
[
[
1342,
24,
1383
],
[
1383,
... | [
[
[
"Romidepsin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Amisulpride"
]
],
[
[
"Romidepsin",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Metronidazole"
],
[
"Metronid... | Romidepsin may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Amisulpride
Romidepsin may cause a moderate interaction that could exacerbate diseases when taken with Famotidine and Fam... |
DB00189 | DB11186 | 459 | 1,609 | [
"DDInter691",
"DDInter1427"
] | Ethchlorvynol | Pentoxyverine | Ethchlorvynol is a sedative and hypnotic drug. It has been used to treat insomnia, but has been largely superseded and is only offered where an intolerance or allergy to other drugs exists. | Pentoxyverine, also referred to as carbetapentane, is a non-opioid central acting antitussive with antimuscarinic, anticonvulsant , and local anesthetic properties. It is an active ingredient in over-the-counter cough suppressants in combination with guaifenesin and H1-receptor antagonists . Pentoxyverine acts on sigma... | Moderate | 1 | [
[
[
459,
24,
1609
]
],
[
[
459,
24,
649
],
[
649,
24,
1609
]
],
[
[
459,
25,
475
],
[
475,
24,
1609
]
],
[
[
459,
24,
649
],
[
649,
... | [
[
[
"Ethchlorvynol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pentoxyverine"
]
],
[
[
"Ethchlorvynol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clofedanol"
],... | Ethchlorvynol may cause a moderate interaction that could exacerbate diseases when taken with Clofedanol and Clofedanol may cause a moderate interaction that could exacerbate diseases when taken with Pentoxyverine
Ethchlorvynol may lead to a major life threatening interaction when taken with Morphine and Morphine may c... |
DB01224 | DB09045 | 623 | 52 | [
"DDInter1553",
"DDInter607"
] | Quetiapine | Dulaglutide | Initially approved by the FDA in 1997, quetiapine is a second-generation atypical antipsychotic used in schizophrenia, major depression, and bipolar disorder. Quetiapine demonstrates a high level of therapeutic efficacy and low risk of adverse effects during long-term treatment. It is well-tolerated and a suitable opti... | Dulaglutide, marketed by Eli Lilly as Trulicity, is a once-weekly subcutaneous glucagon-like peptide-1 (GLP-1) receptor agonist designed using recombinant DNA technology; it has been approved as an adjunct therapy to diet and exercise in the management of 2 diabetes (T2DM). Dulaglutide was initially approved by the FDA... | Moderate | 1 | [
[
[
623,
24,
52
]
],
[
[
623,
24,
170
],
[
170,
23,
52
]
],
[
[
623,
64,
609
],
[
609,
24,
52
]
],
[
[
623,
25,
1154
],
[
1154,
24,
... | [
[
[
"Quetiapine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dulaglutide"
]
],
[
[
"Quetiapine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sitagliptin"
],
[
... | Quetiapine may cause a moderate interaction that could exacerbate diseases when taken with Sitagliptin and Sitagliptin may cause a minor interaction that can limit clinical effects when taken with Dulaglutide
Quetiapine may lead to a major life threatening interaction when taken with Clarithromycin and Clarithromycin m... |
DB00719 | DB06016 | 1,219 | 1,508 | [
"DDInter149",
"DDInter300"
] | Azatadine | Cariprazine | Antihistamines such as azatadine appear to compete with histamine for histamine H1- receptor sites on effector cells. The antihistamines antagonize those pharmacological effects of histamine which are mediated through activation of H1- receptor sites and thereby reduce the intensity of allergic reactions and tissue inj... | Cariprazine is an atypical antipsychotic agent and a piperazine derivative that was first developed in Hungary. It works as a partial agonist at central dopamine D2, dopamine D3, and serotonin 5-HT<sub>1A</sub> receptors and as an antagonist at serotonin 5-HT<sub>2A</sub> receptors. Cariprazine has been investigated in... | Moderate | 1 | [
[
[
1219,
24,
1508
]
],
[
[
1219,
63,
1242
],
[
1242,
24,
1508
]
],
[
[
1219,
24,
1507
],
[
1507,
24,
1508
]
],
[
[
1219,
24,
849
],
[
849... | [
[
[
"Azatadine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cariprazine"
]
],
[
[
"Azatadine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cetirizine"
],
[
... | Azatadine may cause a moderate interaction that could exacerbate diseases when taken with Cetirizine and Cetirizine may cause a moderate interaction that could exacerbate diseases when taken with Cariprazine
Azatadine may cause a moderate interaction that could exacerbate diseases when taken with Dicyclomine and Dicycl... |
DB00307 | DB01229 | 1,101 | 973 | [
"DDInter202",
"DDInter1378"
] | Bexarotene | Paclitaxel (protein-bound) | Bexarotene (Targretin) is an antineoplastic agent indicated by the FDA for Cutaneous T cell lymphoma. It has been used off-label for lung cancer, breast cancer, and Kaposi's sarcoma. | Paclitaxel can cause developmental toxicity, female reproductive toxicity and male reproductive toxicity according to state or federal government labeling requirements. | Moderate | 1 | [
[
[
1101,
24,
973
]
],
[
[
1101,
24,
310
],
[
310,
63,
973
]
],
[
[
1101,
6,
8374
],
[
8374,
45,
973
]
],
[
[
1101,
21,
29267
],
[
29267,
... | [
[
[
"Bexarotene",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Paclitaxel"
]
],
[
[
"Bexarotene",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cabazitaxel"
],
[
... | Bexarotene may cause a moderate interaction that could exacerbate diseases when taken with Paclitaxel
Bexarotene may cause a moderate interaction that could exacerbate diseases when taken with Cabazitaxel and Cabazitaxel may cause a moderate interaction that could exacerbate diseases when taken with Paclitaxel
Bexarote... |
DB00381 | DB11703 | 376 | 405 | [
"DDInter79",
"DDInter9"
] | Amlodipine | Acalabrutinib | Amlodipine, initially approved by the FDA in 1987, is a popular antihypertensive drug belonging to the group of drugs called _dihydropyridine calcium channel blockers_. Due to their selectivity for the peripheral blood vessels, dihydropyridine calcium channel blockers are associated with a lower incidence of myocardial... | To date, acalabrutinib has been used in trials studying the treatment of B-All, myelofibrosis, ovarian cancer, multiple myeloma, and Hodgkin lymphoma, among others. As of October 31, 2017 the FDA approved Astra Zeneca's orally administered Calquence (acalabrutinib, capsules). This Bruton tyrosine kinase (BTK) inhibitor... | Moderate | 1 | [
[
[
376,
24,
405
]
],
[
[
376,
63,
1324
],
[
1324,
24,
405
]
],
[
[
376,
24,
1446
],
[
1446,
24,
405
]
],
[
[
376,
24,
982
],
[
982,
... | [
[
[
"Amlodipine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Acalabrutinib"
]
],
[
[
"Amlodipine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Troglitazone"
],
... | Amlodipine may cause a moderate interaction that could exacerbate diseases when taken with Troglitazone and Troglitazone may cause a moderate interaction that could exacerbate diseases when taken with Acalabrutinib
Amlodipine may cause a moderate interaction that could exacerbate diseases when taken with Lanreotide and... |
DB00372 | DB04861 | 999 | 1,592 | [
"DDInter1793",
"DDInter1271"
] | Thiethylperazine | Nebivolol | A dopamine antagonist that is particularly useful in treating the nausea and vomiting associated with anesthesia, mildly emetic cancer chemotherapy agents, radiation therapy, and toxins. This piperazine phenothiazine does not prevent vertigo or motion sickness. (From AMA Drug Evaluations Annual, 1994, p457) | Nebivolol is a racemic mixture of 2 enantiomers where one is a beta adrenergic antagonist and the other acts as a cardiac stimulant without beta adrenergic activity. Treatment with nebivolol leads to a greater decrease in systolic and diastolic blood pressure than [atenolol], [propranolol], or [pindolol]. Nebivolol and... | Moderate | 1 | [
[
[
999,
24,
1592
]
],
[
[
999,
23,
1283
],
[
1283,
23,
1592
]
],
[
[
999,
23,
460
],
[
460,
62,
1592
]
],
[
[
999,
62,
417
],
[
417,
... | [
[
[
"Thiethylperazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Nebivolol"
]
],
[
[
"Thiethylperazine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Magnesium oxide"
... | Thiethylperazine may cause a minor interaction that can limit clinical effects when taken with Magnesium oxide and Magnesium oxide may cause a minor interaction that can limit clinical effects when taken with Nebivolol
Thiethylperazine may cause a minor interaction that can limit clinical effects when taken with Magnes... |
DB00279 | DB00619 | 1,152 | 1,419 | [
"DDInter1074",
"DDInter909"
] | Liothyronine | Imatinib | Liothyronine is a thyroidal hormone T3 which is normally produced by the thyroid gland in a ratio 4:1 when compared with T4: T3. Liothyronine is the active form of thyroxine which is composed in a basic chemical structure by a tyrosine with bound iodine. The exogenous liothyronine product was developed by King Pharmace... | Imatinib is a small molecule kinase inhibitor that revolutionized the treatment of cancer, particularly chronic myeloid leukemia, in 2001. It was deemed a "miracle drug" due to its clinical success, as oncologist Dr. Brian noted that "complete hematologic responses were observed in 53 of 54 patients with CML treated wi... | Moderate | 1 | [
[
[
1152,
24,
1419
]
],
[
[
1152,
6,
4973
],
[
4973,
45,
1419
]
],
[
[
1152,
21,
28766
],
[
28766,
60,
1419
]
],
[
[
1152,
24,
559
],
[
55... | [
[
[
"Liothyronine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Imatinib"
]
],
[
[
"Liothyronine",
"{u} (Compound) binds {v} (Gene)",
"ABCB1"
],
[
"ABCB1",
"{u} (Gene) is bound by {v} (Compound)",... | Liothyronine (Compound) binds ABCB1 (Gene) and ABCB1 (Gene) is bound by Imatinib (Compound)
Liothyronine (Compound) causes Hypotension (Side Effect) and Hypotension (Side Effect) is caused by Imatinib (Compound)
Liothyronine may cause a moderate interaction that could exacerbate diseases when taken with Estrone and Est... |
DB01432 | DB09340 | 857 | 1,013 | [
"DDInter368",
"DDInter1895"
] | Cholestyramine | Tyropanoic acid | Cholestyramine or colestyramine is a bile acid sequestrant. Bile acid sequestrants are polymeric compounds which serve as ion exchange resins. Cholestyramine resin is quite hydrophilic, but insoluble in water. | Tyropanoic acid is a radiocontrast agent used in cholecystography, the X-ray diagnosis of gallstones under the trade names include Bilopaque, Lumopaque, Tyropaque, and Bilopac. The molecule contains three heavy iodine atoms which obstruct X-rays in the same way as the calcium in bones, which results in a visible image ... | Minor | 0 | [
[
[
857,
23,
1013
]
],
[
[
857,
63,
870
],
[
870,
24,
1586
],
[
1586,
24,
1013
]
],
[
[
857,
63,
870
],
[
870,
63,
1081
],
[
1081,
24,
... | [
[
[
"Cholestyramine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Tyropanoic acid"
]
],
[
[
"Cholestyramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fludrocortisone"... | Cholestyramine may cause a moderate interaction that could exacerbate diseases when taken with Fludrocortisone and Fludrocortisone may cause a moderate interaction that could exacerbate diseases when taken with Levamlodipine and Levamlodipine may cause a moderate interaction that could exacerbate diseases when taken wi... |
DB00011 | DB00087 | 1,451 | 599 | [
"DDInter944",
"DDInter41"
] | Interferon alfa-n1 | Alemtuzumab | Interferon alfa-n1 consists of purified, natural (n is for natural) alpha interferon subtypes, at least two of which are glycosylated. This differs from recombinant alpha interferons, which are individual non-glycosylated proteins produced from individual alpha interferon genes. | Alemtuzumab is a humanized monoclonal antibody specific to lymphocyte antigens. It is a recombinant DNA-derived humanized monoclonal antibody (Campath-1H) that is directed against the 21-28 kD cell surface glycoprotein, CD52. The Campath-1H antibody is an IgG1 kappa with the human variable framework and constant region... | Moderate | 1 | [
[
[
1451,
24,
599
]
],
[
[
1451,
24,
597
],
[
597,
63,
599
]
],
[
[
1451,
24,
367
],
[
367,
24,
599
]
],
[
[
1451,
25,
139
],
[
139,
... | [
[
[
"Interferon alfa-n1",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Alemtuzumab"
]
],
[
[
"Interferon alfa-n1",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Chloramphe... | Interferon alfa-n1 may cause a moderate interaction that could exacerbate diseases when taken with Chloramphenicol and Chloramphenicol may cause a moderate interaction that could exacerbate diseases when taken with Alemtuzumab
Interferon alfa-n1 may cause a moderate interaction that could exacerbate diseases when taken... |
DB08907 | DB09100 | 1,344 | 320 | [
"DDInter280",
"DDInter1799"
] | Canagliflozin | Thyroid, porcine | Canagliflozin, also known as _Invokana_, is a sodium-glucose cotransporter 2 (SGLT2) inhibitor used in the management of type 2 diabetes mellitus along with lifestyle changes including diet and exercise [FDA label]. It was initially approved by the FDA in 2013 for the management of diabetes and later approved in 2018 f... | Thyroid extract is dried and powdered thyroid glands from pigs containing tiiodothyronine (T3) and thyroxine (T4) used to supplement low or absent thyroid activity.[A190831,L11755] Thyroid extract has been described in literature to treat hypothyroidism since 1891 but its use dates back as far as the 6th century. Thyro... | Moderate | 1 | [
[
[
1344,
24,
320
]
],
[
[
1344,
63,
417
],
[
417,
23,
320
]
],
[
[
1344,
63,
1144
],
[
1144,
24,
320
]
],
[
[
1344,
24,
1296
],
[
1296,
... | [
[
[
"Canagliflozin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Thyroid, porcine"
]
],
[
[
"Canagliflozin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sucralfate"
... | Canagliflozin may cause a moderate interaction that could exacerbate diseases when taken with Sucralfate and Sucralfate may cause a minor interaction that can limit clinical effects when taken with Thyroid, porcine
Canagliflozin may cause a moderate interaction that could exacerbate diseases when taken with Nateglinide... |
DB01285 | DB04575 | 708 | 35 | [
"DDInter445",
"DDInter1555"
] | Corticotropin | Quinestrol | Corticotropin (ACTH or adrenocorticotropic hormone) is a polypeptide hormone produced and secreted by the pituitary gland. It is an important player in the hypothalamic-pituitary-adrenal axis. | The 3-cyclopentyl ether of ethinyl estradiol. | Moderate | 1 | [
[
[
708,
24,
35
]
],
[
[
708,
24,
890
],
[
890,
1,
35
]
],
[
[
708,
63,
559
],
[
559,
1,
35
]
],
[
[
708,
24,
177
],
[
177,
40,
... | [
[
[
"Corticotropin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Quinestrol"
]
],
[
[
"Corticotropin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Mestranol"
],
... | Corticotropin may cause a moderate interaction that could exacerbate diseases when taken with Mestranol and Mestranol (Compound) resembles Quinestrol (Compound)
Corticotropin may cause a moderate interaction that could exacerbate diseases when taken with Estrone and Estrone (Compound) resembles Quinestrol (Compound)
Co... |
DB00193 | DB11901 | 534 | 913 | [
"DDInter1841",
"DDInter107"
] | Tramadol | Apalutamide | Tramadol is a centrally acting synthetic opioid analgesic and SNRI (serotonin/norepinephrine reuptake-inhibitor) that is structurally related to [codeine] and [morphine]. Due to its good tolerability profile and multimodal mechanism of action, tramadol is generally considered a lower-risk opioid option for the treatmen... | Apalutamide is a potent androgen receptor (AR) antagonist that selectively binds to the ligand-binding domain of AR and blocks AR nuclear translocation or binding to androgen response elements . It has been used in trials studying the treatment of Prostate Cancer, Hepatic Impairment, Prostatic Neoplasms, Castration-Res... | Major | 2 | [
[
[
534,
25,
913
]
],
[
[
534,
23,
112
],
[
112,
23,
913
]
],
[
[
534,
25,
608
],
[
608,
23,
913
]
],
[
[
534,
24,
600
],
[
600,
24,... | [
[
[
"Tramadol",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Apalutamide"
]
],
[
[
"Tramadol",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Metronidazole"
],
[
"Metronidazol... | Tramadol may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Apalutamide
Tramadol may lead to a major life threatening interaction when taken with Lidocaine and Lidocaine may cause a m... |
DB00280 | DB00372 | 494 | 999 | [
"DDInter575",
"DDInter1793"
] | Disopyramide | Thiethylperazine | A class I anti-arrhythmic agent (one that interferes directly with the depolarization of the cardiac membrane and thus serves as a membrane-stabilizing agent) with a depressant action on the heart similar to that of guanidine. It also possesses some anticholinergic and local anesthetic properties. | A dopamine antagonist that is particularly useful in treating the nausea and vomiting associated with anesthesia, mildly emetic cancer chemotherapy agents, radiation therapy, and toxins. This piperazine phenothiazine does not prevent vertigo or motion sickness. (From AMA Drug Evaluations Annual, 1994, p457) | Moderate | 1 | [
[
[
494,
24,
999
]
],
[
[
494,
24,
286
],
[
286,
62,
999
]
],
[
[
494,
63,
352
],
[
352,
24,
999
]
],
[
[
494,
24,
100
],
[
100,
63,... | [
[
[
"Disopyramide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Thiethylperazine"
]
],
[
[
"Disopyramide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Magnesium hydroxi... | Disopyramide may cause a moderate interaction that could exacerbate diseases when taken with Magnesium hydroxide and Magnesium hydroxide may cause a minor interaction that can limit clinical effects when taken with Thiethylperazine
Disopyramide may cause a moderate interaction that could exacerbate diseases when taken ... |
DB00400 | DB11979 | 353 | 1,320 | [
"DDInter843",
"DDInter625"
] | Griseofulvin | Elagolix | An antifungal antibiotic. Griseofulvin may be given by mouth in the treatment of tinea infections. | Elagolix has been used in trials studying the basic science and treatment of Endometriosis, Folliculogenesis, Uterine Fibroids, Heavy Uterine Bleeding, and Heavy Menstrual Bleeding. As of 24 July 2018, however, the U.S. Food and Drug Administration (FDA) approved AbbVie's elagolix under the brand name Orilissa as the f... | Moderate | 1 | [
[
[
353,
24,
1320
]
],
[
[
353,
62,
168
],
[
168,
23,
1320
]
],
[
[
353,
23,
271
],
[
271,
23,
1320
]
],
[
[
353,
24,
1297
],
[
1297,
... | [
[
[
"Griseofulvin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Elagolix"
]
],
[
[
"Griseofulvin",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Bortezomib"
],
[
... | Griseofulvin may cause a minor interaction that can limit clinical effects when taken with Bortezomib and Bortezomib may cause a minor interaction that can limit clinical effects when taken with Elagolix
Griseofulvin may cause a minor interaction that can limit clinical effects when taken with Mirabegron and Mirabegron... |
DB00030 | DB00519 | 1,685 | 1,638 | [
"DDInter934",
"DDInter1843"
] | Insulin human | Trandolapril | Human Insulin, also known as Regular Insulin, is a short-acting form of insulin used for the treatment of hyperglycemia caused by Type 1 and Type 2 Diabetes. Human insulin is produced by recombinant DNA technology and is identical to endogenously produced insulin. Typically prescribed for the management of diabetes mel... | Trandolapril is a non-sulhydryl prodrug that belongs to the angiotensin-converting enzyme (ACE) inhibitor class of medications. It is metabolized to its biologically active diacid form, trandolaprilat, in the liver. Trandolaprilat inhibits ACE, the enzyme responsible for the conversion of angiotensin I (ATI) to angiote... | Moderate | 1 | [
[
[
1685,
24,
1638
]
],
[
[
1685,
24,
954
],
[
954,
40,
1638
]
],
[
[
1685,
24,
170
],
[
170,
63,
1638
]
],
[
[
1685,
24,
1560
],
[
1560,
... | [
[
[
"Insulin human",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Trandolapril"
]
],
[
[
"Insulin human",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Quinapril"
],
... | Insulin human may cause a moderate interaction that could exacerbate diseases when taken with Quinapril and Quinapril (Compound) resembles Trandolapril (Compound)
Insulin human may cause a moderate interaction that could exacerbate diseases when taken with Sitagliptin and Sitagliptin may cause a moderate interaction th... |
DB01254 | DB12161 | 1,213 | 730 | [
"DDInter484",
"DDInter512"
] | Dasatinib | Deutetrabenazine | Dasatinib is an orally available multikinase inhibitor indicated for the treatment of Philadelphia chromosome (Ph)-positive leukemias.[A2224,L45171] Ph is a chromosomal abnormality found in patients with chronic myelogenous leukemia (CML) and acute lymphocytic leukemia (ALL), where the ABL tyrosine kinase and the break... | Deutetrabenazine is a novel, highly selective vesicular monoamine transporter 2 (VMAT2) inhibitor indicated for the management of chorea associated with Huntington’s disease. It is a hexahydro-dimethoxybenzoquinolizine derivative and a deuterated . The presence of deuterium in deutetrabenazine increases the half-lives ... | Moderate | 1 | [
[
[
1213,
24,
730
]
],
[
[
1213,
62,
112
],
[
112,
23,
730
]
],
[
[
1213,
63,
322
],
[
322,
24,
730
]
],
[
[
1213,
64,
1559
],
[
1559,
... | [
[
[
"Dasatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Deutetrabenazine"
]
],
[
[
"Dasatinib",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Metronidazole"
],
... | Dasatinib may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Deutetrabenazine
Dasatinib may cause a moderate interaction that could exacerbate diseases when taken with Epirubicin and ... |
DB00443 | DB00533 | 251 | 1,416 | [
"DDInter195",
"DDInter1613"
] | Betamethasone | Rofecoxib | Betamethasone is a long-acting corticosteroid with immunosuppressive and antiinflammatory properties. It can be used topically to manage inflammatory skin conditions such as eczema, and parenterally to manage several disease states including autoimmune disorders. Betamethasone has potent glucocorticoid activity and neg... | Rofecoxib is used for the treatment of osteoarthritis, rheumatoid arthritis, acute pain in adults, and primary dysmenorrhea, as well as acute treatment of migraine attacks with or without auras. Rofecoxib is a solid. This compound belongs to the stilbenes. These are organic compounds containing a 1,2-diphenylethylene m... | Moderate | 1 | [
[
[
251,
24,
1416
]
],
[
[
251,
24,
1144
],
[
1144,
63,
1416
]
],
[
[
251,
40,
167
],
[
167,
63,
1416
]
],
[
[
251,
1,
891
],
[
891,
... | [
[
[
"Betamethasone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Rofecoxib"
]
],
[
[
"Betamethasone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Nateglinide"
],
... | Betamethasone may cause a moderate interaction that could exacerbate diseases when taken with Nateglinide and Nateglinide may cause a moderate interaction that could exacerbate diseases when taken with Rofecoxib
Betamethasone (Compound) resembles Hydrocortisone (Compound) and Hydrocortisone may cause a moderate interac... |
DB00446 | DB00713 | 597 | 1,138 | [
"DDInter351",
"DDInter1354"
] | Chloramphenicol | Oxacillin | An antibiotic first isolated from cultures of _Streptomyces venezuelae_ in 1947 but now produced synthetically. It has a relatively simple structure and was the first broad-spectrum antibiotic to be discovered. It acts by interfering with bacterial protein synthesis and is mainly bacteriostatic. (From Martindale, The E... | An antibiotic similar to [flucloxacillin] used in resistant staphylococci infections. | Moderate | 1 | [
[
[
597,
24,
1138
]
],
[
[
597,
24,
950
],
[
950,
1,
1138
]
],
[
[
597,
24,
1249
],
[
1249,
40,
1138
]
],
[
[
597,
63,
790
],
[
790,
... | [
[
[
"Chloramphenicol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Oxacillin"
]
],
[
[
"Chloramphenicol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cloxacillin"
]... | Chloramphenicol may cause a moderate interaction that could exacerbate diseases when taken with Cloxacillin and Cloxacillin (Compound) resembles Oxacillin (Compound)
Chloramphenicol may cause a moderate interaction that could exacerbate diseases when taken with Nafcillin and Nafcillin (Compound) resembles Oxacillin (Co... |
DB04946 | DB12500 | 924 | 283 | [
"DDInter907",
"DDInter714"
] | Iloperidone | Fedratinib | Iloperidone is an atypical antipsychotic for the treatment of schizophrenia symptoms. Hoechst Marion Roussel Inc. researched the drug until May 1996. In June 1997 they gave the research rights to Titan Pharmaceuticals, who gave the worldwide development, manufacturing, and marketing rights to Novartis in August 1998. O... | Fedratinib, also known as SAR302503 and TG101348, is a tyrosine kinase inhibitor used to treat intermediate-2 and high risk primary and secondary myelofibrosis.[A183176,L8090] It is an anilinopyrimidine derivative. Fedratinib was granted FDA approval on August 16, 2019. | Moderate | 1 | [
[
[
924,
24,
283
]
],
[
[
924,
25,
351
],
[
351,
23,
283
]
],
[
[
924,
24,
761
],
[
761,
24,
283
]
],
[
[
924,
64,
600
],
[
600,
24,... | [
[
[
"Iloperidone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fedratinib"
]
],
[
[
"Iloperidone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ribociclib"
],
[
"Ribocicl... | Iloperidone may lead to a major life threatening interaction when taken with Ribociclib and Ribociclib may cause a minor interaction that can limit clinical effects when taken with Fedratinib
Iloperidone may cause a moderate interaction that could exacerbate diseases when taken with Saxagliptin and Saxagliptin may caus... |
DB01232 | DB09143 | 1,327 | 313 | [
"DDInter1640",
"DDInter1701"
] | Saquinavir | Sonidegib | Saquinavir is an HIV-1 protease inhibitor used in combination with [ritonavir] and other antiretrovirals for the treatment of human immunodeficiency virus-1 (HIV-1) infection. In 1995 it became the first protease inhibitor approved by the FDA, followed shortly by ritonavir in 1996, and remains in clinical use today due... | Sonidegib is a Hedgehog signaling pathway inhibitor (via smoothened antagonism) developed as an anticancer agent by Novartis. It was FDA approved in 2015 for the treatment of basal cell carcinoma. | Major | 2 | [
[
[
1327,
25,
313
]
],
[
[
1327,
63,
837
],
[
837,
23,
313
]
],
[
[
1327,
25,
478
],
[
478,
24,
313
]
],
[
[
1327,
64,
918
],
[
918,
... | [
[
[
"Saquinavir",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Sonidegib"
]
],
[
[
"Saquinavir",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pantoprazole"
],
[
"Pantopraz... | Saquinavir may cause a moderate interaction that could exacerbate diseases when taken with Pantoprazole and Pantoprazole may cause a minor interaction that can limit clinical effects when taken with Sonidegib
Saquinavir may lead to a major life threatening interaction when taken with Nilotinib and Nilotinib may cause a... |
DB01191 | DB15035 | 1,039 | 503 | [
"DDInter518",
"DDInter1959"
] | Dexfenfluramine | Zanubrutinib | Dexfenfluramine, also marketed under the name Redux, is a serotoninergic anorectic drug. For a fairly limited time during the middle of the nineties, the US FDA had approved it for use in managing weight loss. However, following multiple concerns about the cardiovascular side-effects of the drug, such approval was with... | Zanubrutinib is a novel Bruton's tyrosine kinase (BTK) inhibitor used for the treatment of adult patients with mantle cell lymphoma (MCL) who have received at least one prior therapy. Mantle cell lymphoma is an aggressive mature B-cell non-Hodgkin lymphoma associated with early relapse, poor clinical outcomes, and long... | Moderate | 1 | [
[
[
1039,
24,
503
]
],
[
[
1039,
24,
868
],
[
868,
24,
503
]
],
[
[
1039,
64,
222
],
[
222,
24,
503
]
],
[
[
1039,
25,
39
],
[
39,
2... | [
[
[
"Dexfenfluramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Zanubrutinib"
]
],
[
[
"Dexfenfluramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Vemurafenib"
... | Dexfenfluramine may cause a moderate interaction that could exacerbate diseases when taken with Vemurafenib and Vemurafenib may cause a moderate interaction that could exacerbate diseases when taken with Zanubrutinib
Dexfenfluramine may lead to a major life threatening interaction when taken with Sibutramine and Sibutr... |
DB00365 | DB08875 | 839 | 1,618 | [
"DDInter842",
"DDInter262"
] | Grepafloxacin | Cabozantinib | Grepafloxacin is an oral broad-spectrum quinoline antibacterial agent used to treat bacterial infections. Due to the QTc-prolonging potential, as indicated by the changes in the QT interval on the electrocardiogram, and the risk for cardiovascular adverse events, grepafloxacin was withdrawn in the United States. | Cabozantinib was first approved in 2012 and is a non-specific tyrosine kinase inhibitor. It was initially approved in the US under the brand name Cometriq, which is indicated for the treatment of metastatic medullary thyroid cancer. In 2016, a capsule formulation (Cabometyx) was approved for the treatment of advanced r... | Major | 2 | [
[
[
839,
25,
1618
]
],
[
[
839,
23,
112
],
[
112,
23,
1618
]
],
[
[
839,
24,
723
],
[
723,
24,
1618
]
],
[
[
839,
24,
384
],
[
384,
... | [
[
[
"Grepafloxacin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Cabozantinib"
]
],
[
[
"Grepafloxacin",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Metronidazole"
],
[
"M... | Grepafloxacin may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Cabozantinib
Grepafloxacin may cause a moderate interaction that could exacerbate diseases when taken with Aprepitant ... |
DB00543 | DB11718 | 87 | 927 | [
"DDInter82",
"DDInter640"
] | Amoxapine | Encorafenib | Amoxapine, the <i>N</i>-demethylated derivative of the antipsychotic agent loxapine, is a dibenzoxazepine-derivative tricyclic antidepressant (TCA). TCAs are structurally similar to phenothiazines. They contain a tricyclic ring system with an alkyl amine substituent on the central ring. In non-depressed individuals, am... | Encorafenib, also known as _BRAFTOVI_, is a kinase inhibitor. Encorafenib inhibits BRAF gene, which encodes for B-raf protein, which is a proto-oncogene involved in various genetic mutations. This protein plays a role in regulating the MAP kinase/ERK signaling pathway, which impacts cell division, differentiation, and ... | Moderate | 1 | [
[
[
87,
24,
927
]
],
[
[
87,
23,
112
],
[
112,
23,
927
]
],
[
[
87,
24,
659
],
[
659,
24,
927
]
],
[
[
87,
63,
1010
],
[
1010,
24,
... | [
[
[
"Amoxapine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Encorafenib"
]
],
[
[
"Amoxapine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Metronidazole"
],
[
... | Amoxapine may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Encorafenib
Amoxapine may cause a moderate interaction that could exacerbate diseases when taken with Vilanterol and Vilan... |
DB00950 | DB05381 | 1,413 | 172 | [
"DDInter732",
"DDInter863"
] | Fexofenadine | Histamine | Fexofenadine is an over-the-counter second-generation antihistamine used in the treatment of various allergic symptoms. It is selective for the H<sub>1</sub> receptor, carries little-to-no activity at off-targets, and does not cross the blood-brain barrier - this is in contrast to previous first-generation antihistamin... | A depressor amine derived by enzymatic decarboxylation of histidine. It is a powerful stimulant of gastric secretion, a constrictor of bronchial smooth muscle, a vasodilator, and also a centrally acting neurotransmitter. | Moderate | 1 | [
[
[
1413,
24,
172
]
],
[
[
1413,
1,
1242
],
[
1242,
24,
172
]
],
[
[
1413,
6,
4973
],
[
4973,
45,
1264
],
[
1264,
24,
172
]
],
[
[
1413,
... | [
[
[
"Fexofenadine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Histamine"
]
],
[
[
"Fexofenadine",
"{u} (Compound) resembles {v} (Compound)",
"Cetirizine"
],
[
"Cetirizine",
"{u} may cause a mode... | Fexofenadine (Compound) resembles Cetirizine (Compound) and Cetirizine may cause a moderate interaction that could exacerbate diseases when taken with Histamine
Fexofenadine (Compound) binds ABCB1 (Gene) and ABCB1 (Gene) is bound by Doxepin (Compound) and Doxepin may cause a moderate interaction that could exacerbate d... |
DB00620 | DB11601 | 175 | 1,270 | [
"DDInter1855",
"DDInter1889"
] | Triamcinolone | Tuberculin purified protein derivative | Triamcinolone is a corticosteroid used to treat various inflammatory conditions in the body from allergic rhinitis to acute exacerbations of multiple sclerosis. Triamcinolone can be used as a one time adjunct treatment of osteoarthritic knee pain, or first line as a topical treatment of corticosteroid responsive dermat... | Tuberculin Purified Protein Derivative (PPD) is a sterile aqueous solution of a purified protein fraction for intradermal administration as an aid in the diagnosis of tuberculosis. The diagnostic test is commonly referred to as the Mantoux test which serves to minimize the risk of transmission of infection with *Mycoba... | Moderate | 1 | [
[
[
175,
24,
1270
]
],
[
[
175,
24,
1531
],
[
1531,
24,
1270
]
],
[
[
175,
64,
1064
],
[
1064,
24,
1270
]
],
[
[
175,
40,
1486
],
[
1486,
... | [
[
[
"Triamcinolone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tuberculin purified protein derivative"
]
],
[
[
"Triamcinolone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
... | Triamcinolone may cause a moderate interaction that could exacerbate diseases when taken with Canakinumab and Canakinumab may cause a moderate interaction that could exacerbate diseases when taken with Tuberculin purified protein derivative
Triamcinolone may lead to a major life threatening interaction when taken with ... |
DB06595 | DB11827 | 1,491 | 433 | [
"DDInter1214",
"DDInter669"
] | Midostaurin | Ertugliflozin | Midostaurin (as Rydapt) is a multitarget kinase inhibitor for the treatment for adult patients with newly diagnosed acute myeloid leukemia (AML) who have a specific genetic mutation called FLT3. It was initially characterized as a potential broad-spectrum antineoplastic agent, with activity toward diverse solid and hem... | Ertugliflozin is a sodium-dependent glucose cotransporter-2 (SGLT2) inhibitor used to treat type II diabetes mellitus. It works to block glucose reabsorption from the glomerulus. Ertugliflozin was first approved by the FDA in December 2017.[A261951, L1132] It was also approved by the European Commission in March 2018. | Moderate | 1 | [
[
[
1491,
24,
433
]
],
[
[
1491,
24,
1654
],
[
1654,
63,
433
]
],
[
[
1491,
64,
695
],
[
695,
24,
433
]
],
[
[
1491,
63,
959
],
[
959,
... | [
[
[
"Midostaurin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ertugliflozin"
]
],
[
[
"Midostaurin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Somapacitan"
],
... | Midostaurin may cause a moderate interaction that could exacerbate diseases when taken with Somapacitan and Somapacitan may cause a moderate interaction that could exacerbate diseases when taken with Ertugliflozin
Midostaurin may lead to a major life threatening interaction when taken with Clozapine and Clozapine may c... |
DB00472 | DB12130 | 758 | 1,017 | [
"DDInter758",
"DDInter1094"
] | Fluoxetine | Lorlatinib | Fluoxetine is a 2nd generation antidepressant categorized as a selective serotonin reuptake inhibitor (SSRI). It gained FDA approval in 1987 and although it was initially intended for the treatment of depression, today it is commonly prescribed to manage depression in addition to various other pathologies. | Lorlatinib is a third-generation ALK tyrosine kinase inhibitor (TKI) for patients with ALK-positive metastatic non-small cell lung cancer which was first approved by the US FDA in November of 2018. It was subsequently approved by the EMA in 2019 for the treatment of select patients with previously treated advanced ALK-... | Moderate | 1 | [
[
[
758,
24,
1017
]
],
[
[
758,
63,
590
],
[
590,
24,
1017
]
],
[
[
758,
24,
1421
],
[
1421,
63,
1017
]
],
[
[
758,
24,
1491
],
[
1491,
... | [
[
[
"Fluoxetine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lorlatinib"
]
],
[
[
"Fluoxetine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Acetohexamide"
],
[... | Fluoxetine may cause a moderate interaction that could exacerbate diseases when taken with Acetohexamide and Acetohexamide may cause a moderate interaction that could exacerbate diseases when taken with Lorlatinib
Fluoxetine may cause a moderate interaction that could exacerbate diseases when taken with Betrixaban and ... |
DB01394 | DB01611 | 1,554 | 1,487 | [
"DDInter431",
"DDInter893"
] | Colchicine | Hydroxychloroquine | Colchicine is an alkaloid drug derived from a plant belonging to the Lily family, known as _Colchicum autumnale_, or "autumn crocus." Its use was first approved by the FDA in 1961. Colchicine is used in the treatment of gout flares and Familial Mediterranean fever, and prevention of major cardiovascular events. It has ... | Hydroxychloroquine is a racemic mixture consisting of an R and S enantiomer. Hydroxychloroquine is an aminoquinoline like [chloroquine]. It is a commonly prescribed medication in the treatment of uncomplicated malaria, rheumatoid arthritis, chronic discoid lupus erythematosus, and systemic lupus erythematosus. Hydroxyc... | Moderate | 1 | [
[
[
1554,
24,
1487
]
],
[
[
1554,
21,
28658
],
[
28658,
60,
1487
]
],
[
[
1554,
64,
723
],
[
723,
24,
1487
]
],
[
[
1554,
63,
168
],
[
168... | [
[
[
"Colchicine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Hydroxychloroquine"
]
],
[
[
"Colchicine",
"{u} (Compound) causes {v} (Side Effect)",
"Vomiting"
],
[
"Vomiting",
"{u} (Side Effect) i... | Colchicine (Compound) causes Vomiting (Side Effect) and Vomiting (Side Effect) is caused by Hydroxychloroquine (Compound)
Colchicine may lead to a major life threatening interaction when taken with Aprepitant and Aprepitant may cause a moderate interaction that could exacerbate diseases when taken with Hydroxychloroqui... |
DB01059 | DB11837 | 956 | 1,297 | [
"DDInter1313",
"DDInter1351"
] | Norfloxacin | Osilodrostat | A synthetic fluoroquinolone (fluoroquinolones) with broad-spectrum antibacterial activity against most gram-negative and gram-positive bacteria. Norfloxacin inhibits bacterial DNA gyrase. | Osilodrostat is an inhibitor of 11β-hydroxylase (also referred to as CYP11B1), the enzyme that catalyzes the final step in the biosynthesis of endogenous cortisol. It is used to lower circulating cortisol levels in the treatment of Cushing's disease, a disorder in which cortisol levels are chronically and supraphysiolo... | Moderate | 1 | [
[
[
956,
24,
1297
]
],
[
[
956,
62,
112
],
[
112,
23,
1297
]
],
[
[
956,
24,
401
],
[
401,
24,
1297
]
],
[
[
956,
63,
1555
],
[
1555,
... | [
[
[
"Norfloxacin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Osilodrostat"
]
],
[
[
"Norfloxacin",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Metronidazole"
],
... | Norfloxacin may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Osilodrostat
Norfloxacin may cause a moderate interaction that could exacerbate diseases when taken with Promethazine an... |
DB00400 | DB11652 | 353 | 1,155 | [
"DDInter843",
"DDInter1891"
] | Griseofulvin | Tucatinib | An antifungal antibiotic. Griseofulvin may be given by mouth in the treatment of tinea infections. | Tucatinib is a kinase inhibitor drug used with [trastuzumab] and [capecitabine] in the treatment of unresectable or metastatic HER-2 positive breast cancer. It was developed by Seattle Genetics and approved by the FDA on April 17, 2020. Tucatinib is a promising new treatment for patients with metastatic breast cancer w... | Moderate | 1 | [
[
[
353,
24,
1155
]
],
[
[
353,
62,
1101
],
[
1101,
23,
1155
]
],
[
[
353,
24,
1424
],
[
1424,
24,
1155
]
],
[
[
353,
24,
466
],
[
466,
... | [
[
[
"Griseofulvin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tucatinib"
]
],
[
[
"Griseofulvin",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Bexarotene"
],
[
... | Griseofulvin may cause a minor interaction that can limit clinical effects when taken with Bexarotene and Bexarotene may cause a minor interaction that can limit clinical effects when taken with Tucatinib
Griseofulvin may cause a moderate interaction that could exacerbate diseases when taken with Quinine and Quinine ma... |
DB00775 | DB01240 | 1,226 | 885 | [
"DDInter1818",
"DDInter657"
] | Tirofiban | Epoprostenol | Tirofiban prevents the blood from clotting during episodes of chest pain or a heart attack, or while the patient is undergoing a procedure to treat a blocked coronary artery. It is a non-peptide reversible antagonist of the platelet glycoprotein (GP) IIb/IIIa receptor, and inhibits platelet aggregation. | A prostaglandin that is a powerful vasodilator and inhibits platelet aggregation. It is biosynthesized enzymatically from prostaglandin endoperoxides in human vascular tissue. The sodium salt has been also used to treat primary pulmonary hypertension. | Moderate | 1 | [
[
[
1226,
24,
885
]
],
[
[
1226,
63,
1061
],
[
1061,
1,
885
]
],
[
[
1226,
21,
28936
],
[
28936,
60,
885
]
],
[
[
1226,
23,
539
],
[
539,
... | [
[
[
"Tirofiban",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Epoprostenol"
]
],
[
[
"Tirofiban",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Treprostinil"
],
[
... | Tirofiban may cause a moderate interaction that could exacerbate diseases when taken with Treprostinil and Treprostinil (Compound) resembles Epoprostenol (Compound)
Tirofiban (Compound) causes Hyperhidrosis (Side Effect) and Hyperhidrosis (Side Effect) is caused by Epoprostenol (Compound)
Tirofiban may cause a minor in... |
DB00242 | DB11834 | 1,064 | 1,303 | [
"DDInter392",
"DDInter849"
] | Cladribine | Guselkumab | An antineoplastic agent used in the treatment of lymphoproliferative diseases including hairy-cell leukemia. | Guselkumab is a human immunoglobulin G1 lambda (IgG1λ) monoclonal antibody that selectively blocks interleukin-23. IL-23 is an inflammatory cytokine that activates the CD4+ T-helper (Th17) cell pathway to mediate the inflammatory cascade that induces psoriatic plaque formation . In clinical trials, guselkumab demonstra... | Major | 2 | [
[
[
1064,
25,
1303
]
],
[
[
1064,
63,
1461
],
[
1461,
23,
1303
]
],
[
[
1064,
24,
949
],
[
949,
24,
1303
]
],
[
[
1064,
25,
713
],
[
713,
... | [
[
[
"Cladribine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Guselkumab"
]
],
[
[
"Cladribine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Vitamin E"
],
[
"Vitamin E",... | Cladribine may cause a moderate interaction that could exacerbate diseases when taken with Vitamin E and Vitamin E may cause a minor interaction that can limit clinical effects when taken with Guselkumab
Cladribine may cause a moderate interaction that could exacerbate diseases when taken with Clostridium tetani toxoid... |
DB00087 | DB01610 | 599 | 248 | [
"DDInter41",
"DDInter1912"
] | Alemtuzumab | Valganciclovir | Alemtuzumab is a humanized monoclonal antibody specific to lymphocyte antigens. It is a recombinant DNA-derived humanized monoclonal antibody (Campath-1H) that is directed against the 21-28 kD cell surface glycoprotein, CD52. The Campath-1H antibody is an IgG1 kappa with the human variable framework and constant region... | Valganciclovir hydrochloride (Valcyte, manufactured by Roche) is an antiviral medication used to treat cytomegalovirus infections. As the L-valyl ester of ganciclovir, it is actually a prodrug for ganciclovir. After oral administration, it is rapidly converted to ganciclovir by intestinal and hepatic esterases. | Moderate | 1 | [
[
[
599,
24,
248
]
],
[
[
599,
24,
563
],
[
563,
1,
248
]
],
[
[
599,
24,
1101
],
[
1101,
24,
248
]
],
[
[
599,
63,
669
],
[
669,
24... | [
[
[
"Alemtuzumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Valganciclovir"
]
],
[
[
"Alemtuzumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ganciclovir"
],
... | Alemtuzumab may cause a moderate interaction that could exacerbate diseases when taken with Ganciclovir and Ganciclovir (Compound) resembles Valganciclovir (Compound)
Alemtuzumab may cause a moderate interaction that could exacerbate diseases when taken with Bexarotene and Bexarotene may cause a moderate interaction th... |
DB00035 | DB06204 | 1,314 | 768 | [
"DDInter507",
"DDInter1746"
] | Desmopressin | Tapentadol | Desmopressin (dDAVP), a synthetic analogue of 8-arginine vasopressin (ADH), is an antidiuretic peptide drug modified by deamination of 1-cysteine and substitution of 8-L-arginine by 8-D-arginine. ADH is an endogenous pituitary hormone that has a crucial role in the control of the water content in the body. Upon release... | Tapentadol is a centrally-acting synthetic analgesic with a dual mechanism of action. It is a mu-opioid receptor agonist that also inhibits norepinephrine reuptake.[A260721, A36596] Tapentadol was first approved by the FDA on November 20, 2008. The extended-release formulation of tapentadol was also approved by the FDA... | Moderate | 1 | [
[
[
1314,
24,
768
]
],
[
[
1314,
21,
28692
],
[
28692,
60,
768
]
],
[
[
1314,
24,
1148
],
[
1148,
24,
768
]
],
[
[
1314,
24,
407
],
[
407,... | [
[
[
"Desmopressin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tapentadol"
]
],
[
[
"Desmopressin",
"{u} (Compound) causes {v} (Side Effect)",
"Mental disorder"
],
[
"Mental disorder",
"{u} (Side... | Desmopressin (Compound) causes Mental disorder (Side Effect) and Mental disorder (Side Effect) is caused by Tapentadol (Compound)
Desmopressin may cause a moderate interaction that could exacerbate diseases when taken with Isoprenaline and Isoprenaline may cause a moderate interaction that could exacerbate diseases whe... |
DB00683 | DB00792 | 1,382 | 832 | [
"DDInter1212",
"DDInter1878"
] | Midazolam | Tripelennamine | Midazolam is a short-acting hypnotic-sedative drug with anxiolytic, muscle relaxant, anticonvulsant, sedative, hypnotic, and amnesic properties. It belongs to a class of drugs called _benzodiazepines_. This drug is unique from others in this class due to its rapid onset of effects and short duration of action. Midazola... | A histamine H1 antagonist with low sedative action but frequent gastrointestinal irritation. It is used to treat asthma; HAY fever; urticaria; and rhinitis; and also in veterinary applications. Tripelennamine is administered by various routes, including topically. | Moderate | 1 | [
[
[
1382,
24,
832
]
],
[
[
1382,
24,
100
],
[
100,
63,
832
]
],
[
[
1382,
24,
649
],
[
649,
1,
832
]
],
[
[
1382,
63,
1594
],
[
1594,
... | [
[
[
"Midazolam",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tripelennamine"
]
],
[
[
"Midazolam",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Brompheniramine"
],
... | Midazolam may cause a moderate interaction that could exacerbate diseases when taken with Brompheniramine and Brompheniramine may cause a moderate interaction that could exacerbate diseases when taken with Tripelennamine
Midazolam may cause a moderate interaction that could exacerbate diseases when taken with Clofedano... |
DB00321 | DB01067 | 21 | 959 | [
"DDInter78",
"DDInter826"
] | Amitriptyline | Glipizide | Amitriptyline is a tricyclic antidepressant that has been used to treat depression for decades. ELAVIL, a previously approved branded product of amitriptyline, was first approved by the FDA in 1961. Amitriptyline has been investigated in the treatment of pain-related conditions, attributed to its analgesic properties. | Glipizide is an oral hypoglycemic agent in the second-generation sulfonylurea drug class that is used to control blood sugar levels in patients with type 2 diabetes mellitus. It was first introduced in 1984 and is available in various countries including Canada and the U.S. According to the 2018 Clinical Practice Guide... | Moderate | 1 | [
[
[
21,
24,
959
]
],
[
[
21,
63,
245
],
[
245,
40,
959
]
],
[
[
21,
24,
1411
],
[
1411,
1,
959
]
],
[
[
21,
6,
8374
],
[
8374,
45,
... | [
[
[
"Amitriptyline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Glipizide"
]
],
[
[
"Amitriptyline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Glimepiride"
],
... | Amitriptyline may cause a moderate interaction that could exacerbate diseases when taken with Glimepiride and Glimepiride (Compound) resembles Glipizide (Compound)
Amitriptyline may cause a moderate interaction that could exacerbate diseases when taken with Tolbutamide and Tolbutamide (Compound) resembles Glipizide (Co... |
DB00731 | DB00812 | 1,144 | 998 | [
"DDInter1269",
"DDInter1451"
] | Nateglinide | Phenylbutazone | Nateglinide is an oral antihyperglycemic agent used for the treatment of non-insulin-dependent diabetes mellitus (NIDDM). It belongs to the meglitinide class of short-acting insulin secretagogues, which act by binding to β cells of the pancreas to stimulate insulin release. Nateglinide is an amino acid derivative that ... | A drug that has anti-inflammatory, antipyretic, and analgesic activities. It is especially effective in the treatment of ankylosing spondylitis. It also is useful in rheumatoid arthritis and Reiter's syndrome (investigational indication). Although phenylbutazone is effective in gouty arthritis, risk/benefit conside... | Moderate | 1 | [
[
[
1144,
24,
998
]
],
[
[
1144,
23,
804
],
[
804,
40,
998
]
],
[
[
1144,
63,
362
],
[
362,
1,
998
]
],
[
[
1144,
24,
97
],
[
97,
40... | [
[
[
"Nateglinide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Phenylbutazone"
]
],
[
[
"Nateglinide",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Sulfinpyrazone"
],
... | Nateglinide may cause a minor interaction that can limit clinical effects when taken with Sulfinpyrazone and Sulfinpyrazone (Compound) resembles Phenylbutazone (Compound)
Nateglinide may cause a moderate interaction that could exacerbate diseases when taken with Phenytoin and Phenytoin (Compound) resembles Phenylbutazo... |
DB01181 | DB14409 | 1,532 | 1,129 | [
"DDInter906",
"DDInter867"
] | Ifosfamide | Human adenovirus e serotype 4 strain cl-68578 antigen | Ifosfamide is a chemotherapeutic agent chemically related to the nitrogen mustards and a synthetic analog of cyclophosphamide. It is active as an alkylating agent and an immunosuppressive agent. | Human adenovirus e serotype 4 strain cl-68578 antigen is a vaccine. | Moderate | 1 | [
[
[
1532,
24,
1129
]
],
[
[
1532,
64,
1057
],
[
1057,
24,
1129
]
],
[
[
1532,
24,
1683
],
[
1683,
24,
1129
]
],
[
[
1532,
63,
134
],
[
134... | [
[
[
"Ifosfamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Human adenovirus e serotype 4 strain cl-68578 antigen"
]
],
[
[
"Ifosfamide",
"{u} may lead to a major life threatening interaction when taken with {v}",
... | Ifosfamide may lead to a major life threatening interaction when taken with Etanercept and Etanercept may cause a moderate interaction that could exacerbate diseases when taken with Human adenovirus e serotype 4 strain cl-68578 antigen
Ifosfamide may cause a moderate interaction that could exacerbate diseases when take... |
DB06603 | DB06717 | 39 | 875 | [
"DDInter1387",
"DDInter778"
] | Panobinostat | Fosaprepitant | Panobinostat is an oral deacetylace (DAC) inhibitor approved on February 23, 2015 by the FDA for the treatment of multiple myeloma. The approval was accelerated based on progression-free survival, therefore confirmatory trials by the sponsor to demonstrate clinical efficacy in multiple myeloma treatment are in progress... | Fosaprepitant is an intravenously administered antiemetic drug. It is a prodrug of Aprepitant. It aids in the prevention of acute and delayed nausea and vomiting associated with chemotherapy treatment. | Moderate | 1 | [
[
[
39,
24,
875
]
],
[
[
39,
63,
723
],
[
723,
1,
875
]
],
[
[
39,
63,
1101
],
[
1101,
23,
875
]
],
[
[
39,
25,
760
],
[
760,
63,
... | [
[
[
"Panobinostat",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fosaprepitant"
]
],
[
[
"Panobinostat",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Aprepitant"
],
... | Panobinostat may cause a moderate interaction that could exacerbate diseases when taken with Aprepitant and Aprepitant (Compound) resembles Fosaprepitant (Compound)
Panobinostat may cause a moderate interaction that could exacerbate diseases when taken with Bexarotene and Bexarotene may cause a minor interaction that c... |
DB00401 | DB01156 | 84 | 593 | [
"DDInter1298",
"DDInter252"
] | Nisoldipine | Bupropion | Nisoldipine is a 1,4-dihydropyridine calcium channel blocker. It acts primarily on vascular smooth muscle cells by stabilizing voltage-gated L-type calcium channels in their inactive conformation. By inhibiting the influx of calcium in smooth muscle cells, nisoldipine prevents calcium-dependent smooth muscle contractio... | Bupropion (also known as the brand name product Wellbutrin®) is a norepinephrine/dopamine-reuptake inhibitor (NDRI) used most commonly for the management of Major Depressive Disorder (MDD), Seasonal Affective Disorder (SAD), and as an aid for smoking cessation. Bupropion exerts its pharmacological effects by weakly inh... | Moderate | 1 | [
[
[
84,
24,
593
]
],
[
[
84,
6,
8374
],
[
8374,
45,
593
]
],
[
[
84,
18,
9385
],
[
9385,
57,
593
]
],
[
[
84,
21,
29243
],
[
29243,
... | [
[
[
"Nisoldipine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bupropion"
]
],
[
[
"Nisoldipine",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)"... | Nisoldipine (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Bupropion (Compound)
Nisoldipine (Compound) downregulates MRPL19 (Gene) and MRPL19 (Gene) is downregulated by Bupropion (Compound)
Nisoldipine (Compound) causes Wheezing (Side Effect) and Wheezing (Side Effect) is caused by Bupropion (Compound)
Ni... |
DB06723 | DB09100 | 115 | 320 | [
"DDInter58",
"DDInter1799"
] | Aluminum hydroxide | Thyroid, porcine | Aluminum hydroxide is an inorganic salt used as an antacid. It is a basic compound that acts by neutralizing hydrochloric acid in gastric secretions. Subsequent increases in pH may inhibit the action of pepsin. An increase in bicarbonate ions and prostaglandins may also confer cytoprotective effects. | Thyroid extract is dried and powdered thyroid glands from pigs containing tiiodothyronine (T3) and thyroxine (T4) used to supplement low or absent thyroid activity.[A190831,L11755] Thyroid extract has been described in literature to treat hypothyroidism since 1891 but its use dates back as far as the 6th century. Thyro... | Moderate | 1 | [
[
[
115,
24,
320
]
],
[
[
115,
63,
417
],
[
417,
23,
320
]
],
[
[
115,
24,
428
],
[
428,
63,
320
]
],
[
[
115,
63,
1411
],
[
1411,
2... | [
[
[
"Aluminum hydroxide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Thyroid, porcine"
]
],
[
[
"Aluminum hydroxide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sucra... | Aluminum hydroxide may cause a moderate interaction that could exacerbate diseases when taken with Sucralfate and Sucralfate may cause a minor interaction that can limit clinical effects when taken with Thyroid, porcine
Aluminum hydroxide may cause a moderate interaction that could exacerbate diseases when taken with F... |
DB00557 | DB00927 | 252 | 1,559 | [
"DDInter895",
"DDInter712"
] | Hydroxyzine | Famotidine | Hydroxyzine is a first-generation histamine H<sub>1</sub>-receptor antagonist of the dephenylmethane and piperazine classes that exhibits sedative, anxiolytic, and antiemetic properties.[A1257,A187589] It was first developed in 1955, and has since remained a relatively common treatment for allergic conditions such as p... | Famotidine is a competitive histamine-2 (H<sub>2</sub>) receptor antagonist that works to inhibit gastric acid secretion. It is commonly used in gastrointestinal conditions related to acid secretion, such as gastric ulcers and gastroesophageal reflux disease (GERD), in adults and children. Compared to other H<sub>2</su... | Moderate | 1 | [
[
[
252,
24,
1559
]
],
[
[
252,
21,
28787
],
[
28787,
60,
1559
]
],
[
[
252,
24,
286
],
[
286,
62,
1559
]
],
[
[
252,
23,
112
],
[
112,
... | [
[
[
"Hydroxyzine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Famotidine"
]
],
[
[
"Hydroxyzine",
"{u} (Compound) causes {v} (Side Effect)",
"Dermatitis"
],
[
"Dermatitis",
"{u} (Side Effect) is ... | Hydroxyzine (Compound) causes Dermatitis (Side Effect) and Dermatitis (Side Effect) is caused by Famotidine (Compound)
Hydroxyzine may cause a moderate interaction that could exacerbate diseases when taken with Magnesium hydroxide and Magnesium hydroxide may cause a minor interaction that can limit clinical effects whe... |
DB00705 | DB09330 | 441 | 985 | [
"DDInter496",
"DDInter1352"
] | Delavirdine | Osimertinib | A potent, non-nucleoside reverse transcriptase inhibitor with activity specific for HIV-1. | Osimertinib is an oral, third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) drug developed by AstraZeneca Pharmaceuticals.[A7926,L43453] Its use is indicated for the treatment of metastatic non-small cell lung cancer (NSCLC) in cases where tumour EGFR expression is positive for the ... | Major | 2 | [
[
[
441,
25,
985
]
],
[
[
441,
63,
168
],
[
168,
23,
985
]
],
[
[
441,
25,
1478
],
[
1478,
24,
985
]
],
[
[
441,
64,
134
],
[
134,
2... | [
[
[
"Delavirdine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Osimertinib"
]
],
[
[
"Delavirdine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bortezomib"
],
[
"Bortezo... | Delavirdine may cause a moderate interaction that could exacerbate diseases when taken with Bortezomib and Bortezomib may cause a minor interaction that can limit clinical effects when taken with Osimertinib
Delavirdine may lead to a major life threatening interaction when taken with Ivacaftor and Ivacaftor may cause a... |
DB00434 | DB01367 | 13 | 1,163 | [
"DDInter459",
"DDInter1572"
] | Cyproheptadine | Rasagiline | Cyproheptadine is a potent competitive antagonist of both serotonin and histamine receptors. It is used primarily to treat allergic symptoms, though it is perhaps more notable for its use in appetite stimulation and its off-label use in the treatment of serotonin syndrome. | Rasagiline is an irreversible inhibitor of monoamine oxidase and is used as a monotherapy in early Parkinson's disease or as an adjunct therapy in more advanced cases. | Moderate | 1 | [
[
[
13,
24,
1163
]
],
[
[
13,
21,
28714
],
[
28714,
60,
1163
]
],
[
[
13,
24,
100
],
[
100,
24,
1163
]
],
[
[
13,
24,
830
],
[
830,
... | [
[
[
"Cyproheptadine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Rasagiline"
]
],
[
[
"Cyproheptadine",
"{u} (Compound) causes {v} (Side Effect)",
"Asthenia"
],
[
"Asthenia",
"{u} (Side Effect) i... | Cyproheptadine (Compound) causes Asthenia (Side Effect) and Asthenia (Side Effect) is caused by Rasagiline (Compound)
Cyproheptadine may cause a moderate interaction that could exacerbate diseases when taken with Brompheniramine and Brompheniramine may cause a moderate interaction that could exacerbate diseases when ta... |
DB01320 | DB09054 | 651 | 384 | [
"DDInter783",
"DDInter905"
] | Fosphenytoin | Idelalisib | Fosphenytoin is a water-soluble phenytoin prodrug used only in hospitals for the treatment of epileptic seizures. It works by slowing down impulses in the brain that cause seizures. Its main mechanism is to block frequency-dependent, use-dependent and voltage-dependent neuronal sodium channels, and therefore limit repe... | Idelalisib is a phosphoinositide 3-kinase inhibitor indicated in the treatment of chronic lymphocytic leukemia (CLL), relapsed follicular B-cell non-Hodgkin lymphoma (FL), and relapsed small lymphocytic lymphoma (SLL). For the treatment of relapsed CLL, it is currently indicated as a second-line agent in combination wi... | Major | 2 | [
[
[
651,
25,
384
]
],
[
[
651,
40,
307
],
[
307,
23,
384
]
],
[
[
651,
25,
1618
],
[
1618,
24,
384
]
],
[
[
651,
63,
58
],
[
58,
24,... | [
[
[
"Fosphenytoin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Idelalisib"
]
],
[
[
"Fosphenytoin",
"{u} (Compound) resembles {v} (Compound)",
"Modafinil"
],
[
"Modafinil",
"{u} may cause a minor interaction th... | Fosphenytoin (Compound) resembles Modafinil (Compound) and Modafinil may cause a minor interaction that can limit clinical effects when taken with Idelalisib
Fosphenytoin may lead to a major life threatening interaction when taken with Cabozantinib and Cabozantinib may cause a moderate interaction that could exacerbate... |
DB00679 | DB01075 | 684 | 1,376 | [
"DDInter1796",
"DDInter569"
] | Thioridazine | Diphenhydramine | A phenothiazine antipsychotic used in the management of psychoses, including schizophrenia, and in the control of severely disturbed or agitated behavior. It has little antiemetic activity. Thioridazine has a higher incidence of antimuscarinic effects, but a lower incidence of extrapyramidal symptoms, than chlorpromazi... | Diphenhydramine - perhaps known most commonly as its brand name formulation Benadryl - is a first-generation H1 receptor antihistamine that is used extensively for the treatment of seasonal allergies, insect bites and stings, and rashes [L5263, L5266, L5269, F3379]. However, it also has antiemetic, antitussive, hypnoti... | Major | 2 | [
[
[
684,
25,
1376
]
],
[
[
684,
24,
649
],
[
649,
63,
1376
]
],
[
[
684,
64,
11
],
[
11,
1,
1376
]
],
[
[
684,
63,
128
],
[
128,
24,... | [
[
[
"Thioridazine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Diphenhydramine"
]
],
[
[
"Thioridazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clofedanol"
],
[
"C... | Thioridazine may cause a moderate interaction that could exacerbate diseases when taken with Clofedanol and Clofedanol may cause a moderate interaction that could exacerbate diseases when taken with Diphenhydramine
Thioridazine may lead to a major life threatening interaction when taken with Toremifene and Toremifene (... |
DB08826 | DB11703 | 1,292 | 405 | [
"DDInter489",
"DDInter9"
] | Deferiprone | Acalabrutinib | Deferiprone is an oral iron chelator used as a second line agent in thalassemia syndromes when iron overload from blood transfusions occurs. Thalassemias are a type of hereditary anaemia due a defect in the production of hemoglobin. As a result, erythropoiesis, the production of new red blood cells, is impaired. FDA ap... | To date, acalabrutinib has been used in trials studying the treatment of B-All, myelofibrosis, ovarian cancer, multiple myeloma, and Hodgkin lymphoma, among others. As of October 31, 2017 the FDA approved Astra Zeneca's orally administered Calquence (acalabrutinib, capsules). This Bruton tyrosine kinase (BTK) inhibitor... | Major | 2 | [
[
[
1292,
25,
405
]
],
[
[
1292,
24,
1384
],
[
1384,
24,
405
]
],
[
[
1292,
64,
690
],
[
690,
24,
405
]
],
[
[
1292,
25,
951
],
[
951,
... | [
[
[
"Deferiprone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Acalabrutinib"
]
],
[
[
"Deferiprone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Magaldrate"
],
[
"Magal... | Deferiprone may cause a moderate interaction that could exacerbate diseases when taken with Magaldrate and Magaldrate may cause a moderate interaction that could exacerbate diseases when taken with Acalabrutinib
Deferiprone may lead to a major life threatening interaction when taken with Rifabutin and Rifabutin may cau... |
DB00159 | DB00569 | 940 | 553 | [
"DDInter903",
"DDInter775"
] | Icosapent | Fondaparinux | Important polyunsaturated fatty acid found in fish oils. It serves as the precursor for the prostaglandin-3 and thromboxane-3 families. A diet rich in eicosapentaenoic acid lowers serum lipid concentration, reduces incidence of cardiovascular disorders, prevents platelet aggregation, and inhibits arachidonic acid conve... | Fondaparinux (Arixtra) is a synthetic anticoagulant agent consisting of five monomeric sugar units and a O-methyl group at the reducing end of the molecule. It is structurally similar to polymeric glycosaminoglycan heparin and heparan sulfate (HS) when they are cleaved into monomeric units. The monomeric sequence in he... | Moderate | 1 | [
[
[
940,
24,
553
]
],
[
[
940,
21,
29203
],
[
29203,
60,
553
]
],
[
[
940,
24,
477
],
[
477,
64,
553
]
],
[
[
940,
63,
1167
],
[
1167,
... | [
[
[
"Icosapent",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fondaparinux"
]
],
[
[
"Icosapent",
"{u} (Compound) causes {v} (Side Effect)",
"Aspartate aminotransferase increased"
],
[
"Aspartate aminotr... | Icosapent (Compound) causes Aspartate aminotransferase increased (Side Effect) and Aspartate aminotransferase increased (Side Effect) is caused by Fondaparinux (Compound)
Icosapent may cause a moderate interaction that could exacerbate diseases when taken with Cilostazol and Cilostazol may lead to a major life threaten... |
DB08893 | DB11978 | 271 | 124 | [
"DDInter1229",
"DDInter822"
] | Mirabegron | Glasdegib | Mirabegron is a sympathomimetic beta-3 adrenergic receptor agonist used to relax the smooth muscle of the bladder in the treatment of urinary frequency and incontinence. It is unique amongst overactive bladder treatment options in that, unlike other treatments such as [solifenacin] and [darifenacin], it lacks significa... | Glasdegib, also known as PF-04449913, is a small-molecule hedgehog signaling inhibitor selected under the group of benzimidazoles. In early research, benzimidazoles attracted large interest as they represented a class of inhibitors with low molecular weight, potent inhibitory activity, and lacking unstable functionalit... | Moderate | 1 | [
[
[
271,
24,
124
]
],
[
[
271,
62,
752
],
[
752,
24,
124
]
],
[
[
271,
23,
98
],
[
98,
24,
124
]
],
[
[
271,
23,
159
],
[
159,
63,
... | [
[
[
"Mirabegron",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Glasdegib"
]
],
[
[
"Mirabegron",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Cimetidine"
],
[
... | Mirabegron may cause a minor interaction that can limit clinical effects when taken with Cimetidine and Cimetidine may cause a moderate interaction that could exacerbate diseases when taken with Glasdegib
Mirabegron may cause a minor interaction that can limit clinical effects when taken with Somatrem and Somatrem may ... |
DB01058 | DB14723 | 978 | 159 | [
"DDInter1510",
"DDInter1026"
] | Praziquantel | Larotrectinib | Praziquantel is a pyrazino-isoquinolein derivative from the thioxantonic group used as a broad anthelmintic spectrum. Specifically, it is known as a treatment of trematodes and cestodes infections such as schistosomiasis, taeniasis, and cysticercosis. The efficacy of praziquantel in treating parasitic flatworms infecti... | Larotrectinib is an orally administered inhibitor of tropomyosin receptor kinase (Trk), a receptor tyrosine kinase activated by neurotrophins which is mutated in a variety of cancer cell types and plays an important role in tumor cell growth and survival. Upon administration, larotrectinib binds to Trk, thereby prevent... | Moderate | 1 | [
[
[
978,
24,
159
]
],
[
[
978,
24,
907
],
[
907,
23,
159
]
],
[
[
978,
24,
1375
],
[
1375,
24,
159
]
],
[
[
978,
63,
307
],
[
307,
2... | [
[
[
"Praziquantel",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Larotrectinib"
]
],
[
[
"Praziquantel",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Doravirine"
],
... | Praziquantel may cause a moderate interaction that could exacerbate diseases when taken with Doravirine and Doravirine may cause a minor interaction that can limit clinical effects when taken with Larotrectinib
Praziquantel may cause a moderate interaction that could exacerbate diseases when taken with Lefamulin and Le... |
DB00741 | DB04834 | 167 | 276 | [
"DDInter885",
"DDInter1571"
] | Hydrocortisone | Rapacuronium | Hydrocortisone, or cortisol, is a glucocorticoid secreted by the adrenal cortex. Hydrocortisone is used to treat immune, inflammatory, and neoplastic conditions.[L10529,L10532,L10535,L10538,L7772,L7321] It was discovered in the 1930s by Edward Kendall and named Compound F, or 17-hydroxycorticosterone. Hydrocortisone wa... | Rapacuronium was withdrawn in 2001 in many countries due to risk of fatal bronchospasm. | Moderate | 1 | [
[
[
167,
24,
276
]
],
[
[
167,
63,
1031
],
[
1031,
24,
276
]
],
[
[
167,
1,
251
],
[
251,
24,
276
]
],
[
[
167,
40,
870
],
[
870,
24... | [
[
[
"Hydrocortisone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Rapacuronium"
]
],
[
[
"Hydrocortisone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Theophylline"
... | Hydrocortisone may cause a moderate interaction that could exacerbate diseases when taken with Theophylline and Theophylline may cause a moderate interaction that could exacerbate diseases when taken with Rapacuronium
Hydrocortisone (Compound) resembles Betamethasone (Compound) and Betamethasone may cause a moderate in... |
DB01206 | DB01610 | 37 | 248 | [
"DDInter1086",
"DDInter1912"
] | Lomustine | Valganciclovir | An alkylating agent of value against both hematologic malignancies and solid tumors. | Valganciclovir hydrochloride (Valcyte, manufactured by Roche) is an antiviral medication used to treat cytomegalovirus infections. As the L-valyl ester of ganciclovir, it is actually a prodrug for ganciclovir. After oral administration, it is rapidly converted to ganciclovir by intestinal and hepatic esterases. | Moderate | 1 | [
[
[
37,
24,
248
]
],
[
[
37,
63,
563
],
[
563,
1,
248
]
],
[
[
37,
21,
29209
],
[
29209,
60,
248
]
],
[
[
37,
63,
1238
],
[
1238,
24... | [
[
[
"Lomustine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Valganciclovir"
]
],
[
[
"Lomustine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ganciclovir"
],
[... | Lomustine may cause a moderate interaction that could exacerbate diseases when taken with Ganciclovir and Ganciclovir (Compound) resembles Valganciclovir (Compound)
Lomustine (Compound) causes Anorexia (Side Effect) and Anorexia (Side Effect) is caused by Valganciclovir (Compound)
Lomustine may cause a moderate interac... |
DB01610 | DB06595 | 248 | 1,491 | [
"DDInter1912",
"DDInter1214"
] | Valganciclovir | Midostaurin | Valganciclovir hydrochloride (Valcyte, manufactured by Roche) is an antiviral medication used to treat cytomegalovirus infections. As the L-valyl ester of ganciclovir, it is actually a prodrug for ganciclovir. After oral administration, it is rapidly converted to ganciclovir by intestinal and hepatic esterases. | Midostaurin (as Rydapt) is a multitarget kinase inhibitor for the treatment for adult patients with newly diagnosed acute myeloid leukemia (AML) who have a specific genetic mutation called FLT3. It was initially characterized as a potential broad-spectrum antineoplastic agent, with activity toward diverse solid and hem... | Moderate | 1 | [
[
[
248,
24,
1491
]
],
[
[
248,
24,
1342
],
[
1342,
24,
1491
]
],
[
[
248,
63,
663
],
[
663,
24,
1491
]
],
[
[
248,
24,
738
],
[
738,
... | [
[
[
"Valganciclovir",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Midostaurin"
]
],
[
[
"Valganciclovir",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Romidepsin"
],... | Valganciclovir may cause a moderate interaction that could exacerbate diseases when taken with Romidepsin and Romidepsin may cause a moderate interaction that could exacerbate diseases when taken with Midostaurin
Valganciclovir may cause a moderate interaction that could exacerbate diseases when taken with Methotrexate... |
DB00719 | DB01114 | 1,219 | 272 | [
"DDInter149",
"DDInter362"
] | Azatadine | Chlorpheniramine | Antihistamines such as azatadine appear to compete with histamine for histamine H1- receptor sites on effector cells. The antihistamines antagonize those pharmacological effects of histamine which are mediated through activation of H1- receptor sites and thereby reduce the intensity of allergic reactions and tissue inj... | A histamine H1 antagonist used in allergic reactions, hay fever, rhinitis, urticaria, and asthma. It has also been used in veterinary applications. One of the most widely used of the classical antihistaminics, it generally causes less drowsiness and sedation than promethazine. | Moderate | 1 | [
[
[
1219,
24,
272
]
],
[
[
1219,
24,
358
],
[
358,
63,
272
]
],
[
[
1219,
63,
128
],
[
128,
24,
272
]
],
[
[
1219,
6,
8374
],
[
8374,
... | [
[
[
"Azatadine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Chlorpheniramine"
]
],
[
[
"Azatadine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Orphenadrine"
],
... | Azatadine may cause a moderate interaction that could exacerbate diseases when taken with Orphenadrine and Orphenadrine may cause a moderate interaction that could exacerbate diseases when taken with Chlorpheniramine
Azatadine may cause a moderate interaction that could exacerbate diseases when taken with Dexbromphenir... |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.